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ABSTRACT
Proteins are ubiquitous in all living organisms, executing the majority of cellular functions in
distinct ways. Understanding a protein’s role necessitates investigating its structure and function, which
are closely related. My research couples these two aspects by delving into the biochemical and structural
characterization of proteins in four distinct systems, all playing central roles in numerous significant
disease progressions. These four original research endeavors were all targeted for structural studies with
a unifying relationship to establish our new structural biochemistry lab. These four systems are: (1)
Gam1, an early adenovirus protein globally inhibiting host SUMOylation; (2) Anthrax toxin complexed
with its cellular receptor; (3) hCRY1, a core component of the circadian rhythm; and (4) an antibody
against cancer cell-surface glycans. Traditional molecular, biochemical, and biophysical techniques such
as molecular cloning, in vitro protein-protein assays, and structure determination have been utilized in
the above mentioned projects to analyze protein functions. All four projects have obtained results at
different stages, two have reached key milestones and two have established knowledge towards the
future steps to structural analyses. All of these projects have built a strong foundation for the current and
future success of the lab. Each project has contributed in general to understand the biological process at
the molecular level. In addition, the four chosen systems involve investigations of protein-protein,
protein-carbohydrate and protein-DNA interactions, all are critical for elucidating how biomolecules
work collaboratively to perform the function of the cell. The results from these projects will ultimately
improve our ability to develop novel biological and biomedical applications in hopes of developing
treatments for the diseases.
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CHAPTER 1:
BIOCHEMICAL CHARACTERIZATION OF AN EARLY GENE PRODUCT OF AN ADENOVIRUS GAM1

1.1

INTRODUCTION TO GAM1
After folding into their proper three-dimensional shapes, many proteins will undergo

posttranslational modifications (PTM) in order to fully attain their final function [1, 2]. Moreover, many
PTMs are reversible, which have the ability to switch protein functionality among different biological
isoforms [3-5]. The protein under investigation is Gam1, an early gene product of adenovirus Chicken
Embryo Lethal Orphan (CELO) characterized by a molecular weight of 31 kDa. It is involved in the
regulation of viral replication. Gam1 was discovered serendipitously as a novel anti-apoptotic protein
upon screening for viral proteins that regulate cellular apoptosis [6]. In 1996, Susana Chiocca and
colleagues originated their research endeavor by sequencing and characterizing the genomic
organization of avian adenovirus (CELO). Further evidence shows that Gam1, a non-structural protein,
plays important roles in controlling host cellular machinery so that the virus may effectively replicate
itself [7, 8]. In 2002, Gam1 was also found to disrupt transcriptional regulation by inactivation of
Histone Deacetylase 1 (HDAC1), an enzyme that regulates gene expression in cells. Most recently,
Gam1 was discovered to have a unique function of modulating SUMOylation (Small ubiquitin-related
Modifier) [9-11], a reversible PTM that alters protein function. As a result, Gam1 could manage to
accomplish the aforementioned multiple tasks. It is still unclear whether Gam1 performs its function via
the direct modulation of gene expression, or through PTMs such as the SUMOylation pathway. Proteins
found in subnuclear compartments are heavily SUMO modified, a probable mechanism against viral
infections [12-14]. Furthermore, the mechanism was recently elucidated of how Gam1 inhibits host
SUMOylation [15, 16] described in detail below. All in all Gam1 is not only the first viral protein
discovered to impact host SUMOylation, but also the only viral protein to inhibit SUMOylation
1

globally. Understanding the mechanism of Gam1’s function will build the foundation to utilize it as a
tool to obliterate SUMOylation in targeted cells. Aspects of what SUMOylation entail, how viruses
intertwine into the modification to this cellular process, and how Gam1’s functions can alter the normal
process of SUMOylation will be discussed in this chapter. Thereafter, research performed with Gam1
will be demonstrated.

1.1.1

SUMOYLATION AND VIRUSES
SUMO (Small ubiquitin-related Modifier) was discovered nearly twenty years ago, when

investigation of yeast proteins [17], soon afterward a human protein [18] was altered by SUMO as well.
From these studies, it was determined that SUMO would effectively be covalently bound to target
proteins impinging on their ability to establish new protein-protein interactions. This attachment of
SUMO is a reversible modification. As a result, SUMOylation can switch proteins’ function as well as
redirect their localization within the cell [19]. In the time since these discoveries, hundreds of
experiments conducted have demonstrated numerous, a quantity now in the hundreds, targets of SUMO.
Each of these SUMOylated targets are capable of assuming a completely different role in their
functionality. Experiments have shown that SUMOylation inhibits protein-protein interactions in a
variety of ways including the additional surface of SUMO itself, obstruction of binding sites, or
potential structural modifications that have occurred due to the SUMO modification [19]. As a result,
SUMO can stabilize, de-localize, or label a protein for degradation. In terms of molecular size, SUMO
tags are typically around 10 kilo Daltons (kDa), and their overall three dimensional structures are similar
to those of ubiquitins [20-22]. SUMOylation is found throughout eukaryotes, with variations in the
number of SUMO genes. For instance, humans have four genes encoding SUMO tags, while
Drosophila melanogaster only has one [23]. Similar to the ubiquitination reaction, SUMOylation
occurs when an isopeptide bond is formed between the C-terminal glycine (Gly) of SUMO and the
2
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amino group of a lysine residue in the target protein. The enzymatic cascade that ensues for both
SUMOylation and ubiquitination processes requires the activities of three classes of enzymes: E1, E2,
and E3. The cascade begins with activation of the tags catalyzed by the E1 enzymes in ubiquitination
and SUMO Activation Enzymes (SAE 1 and SAE2) in SUMOylation. Afterward, the second step is
conjugation catalyzed by the E2 enzymes of each system. Finally, substrate modification is catalyzed by
the E3 ligases, enzymes that catalyze the transfer of tags from the conjugating enzymes E2 to the target
substrates [9, 24]. It is the different E3 ligases utilized by the two systems that define the specificity of
SUMOylation and ubiquitination [19].
As abovementioned, the attachment of SUMO to target substrates has been shown to play a
variety of roles in protein stability, as well as regulation of transcription by influencing transcription
factors or directly activating the process of transcription [9]. Given that viruses require a host to
replicate, viruses must produce an environment suitable for their reproduction. One of the important
functions that they must possess is to control components responsible for transcription in host cells.
Evidence has shown that viruses can passively adapt to host SUMOylation by modifying cellular and/or
viral proteins. An example is the vaccinia virus protein A40R, which is SUMOylated and remains in the
cytosolic side of the Endoplasmic Reticulum, where viral replication occurs [25]. Viruses also exploit
the SUMOylation pathway for viral assembly, one example is the SUMOylation of M1 protein of
Influenza A virus [26]. Conversely, some viruses have been found to produce specific proteins, which
directly control host SUMOylation in a concerted effort to survive and proliferate [27]. One example is
a viral protein from Kaposi’s sarcoma-associated herpes virus (KSHV) that acts as a transcriptional
regulator, which arrests the cell cycle effectively preventing apoptosis so that viral replication continues
[28]. Another example of viral utilization of SUMOylation is for immune evasion. For instance, the
Ebola Zaire Virus (EBOV) protein VP35 increases the SUMOylation of a principle cellular component
that produces a pro-inflammatory response, thereby weakening the host immune system [29].
3

1.1.2

GAM1 AND SUMOYLATION
Gam1 was initially believed to facilitate viral replication by affecting host gene expression [9,

11]. Gam1’s expression has been shown to increase transcription from various promoters [24]. A Gam1
mutant was generated to test its effect on transcription. The mutant was unable to activate transcription
[8]. Moreover, it has been demonstrated that viruses alter subnuclear structures, such as the chromatinremodeling enzyme histone deacetylase 1 (HDAC1) [11]. HDAC1 prevents transcription by removing
acetyl groups from the amino terminal domain of histones, allowing for a favorable interaction between
histones and DNA. Proteins found in subnuclear compartments are heavily SUMO modified, and the
modifications taking place are known mechanisms against viral infections. This led to the discovery of
the true mechanism of how Gam1 facilitate viral replication via interference with the host
SUMOylation. Gam1 disrupts these proteins, which led to the discovery that SUMO-1 is diminished in
the nucleus [10]. Gam1 expression diminishes global nuclear SUMOylation, by degradation of the
SUMO E1 heterodimer (SAE1/SAE2), which ultimately eliminates the SUMOylation pathway [9].
SAE1/2, mediated by Gam1, is incorporated into ubiquitin ligase complexes leading to degradation [16,
24]. It is noteworthy that viruses exploit these cellular degradation pathways to manipulate normal cell
processes—such as SUMOylation by Gam1 [24]. Gam1 was the first viral protein discovered to
provoke the disappearance of SUMO E1 and E2 proteins, regulating host cell proteins [9].
In vitro research with Gam1 and loss of SUMO occurred in a dose dependent manner, and only
when an intact SUMO-E1 complex was not already established [9]. It was revealed that Gam1 does not
compete with SUMO-E1 binding; on the contrary, E1 disappeared [9]. These findings were supported
when it was shown that the E1 heterodimer was eliminated in vivo while CELO infection was taking
place [9]. When a proteasome inhibitor associated with ubiquitination is added, SAE1 and SAE2
heterodimer formation is restored, implicating Gam1’s function links to the ubiquitin-like pathway [9].
4

The Ubiquitin Proteasome System (UPS) is an essential moderator of cellular processes, which is carried
out via governing protein degradation [30]. As mentioned above, similar to SUMOylation,
ubiquitination is carried out by the same enzymatic cascade containing: E1 activating enzyme, the E2
conjugating enzymes, and the E3 ligases. The usage of different E3 ligases is where differences are seen
between the SUMOylation and ubiquitination pathways [31, 32]. Given Gam1’s association in these
PTM pathways, bioinformatical investigations were carried out to define a conserved domain utilized in
these modifications [33]. Further analyses of Gam1 demonstrated two motifs: suppressor of cytokine
signaling (SOCS) and BC-Box-like-motif (BC box), which are required for establishing a complex
containing ubiquitin like proteins, elongin B/C and E3 Ligases, Cullins 2 and 5 [33]. The N-terminal
motif termed BC Box interacts with Elongins B, an ubitquitin-like protein, and C, an S-phase kinaseassociated protein 1 (Skp1), both of which are involved in protein degradation [34]. Evidence suggests
that Elongin BC is central to SOCS complexes and renders Elongin BC as a multifunctional complex
capable of regulating cell processes in a variety of ways [34]. The SOCS box, typically found at the Cterminus of a protein, serves as a link between the substrate binding domain and that of the protein(s)
associated with aforementioned ubiquitination E3 ligase complexes [24, 33, 35]. The discovery of
SOCS in Gam1 is an important breakthrough. Given that SOCS containing proteins play a grand role in
mediating protein elimination by targeting for polyubiquitination and their eventual removal via the
proteasome, it is rational to conclude that Gam1 destroys SUMOylation via protein degradations.
Another major contributor in the complex is the E3 ligase. Given the multiple existences of E3 ligases
in both SUMOylation and ubiquitination pathways, members have been classified into different families
based on their structure and functionality. One of the classes is the Cullin RING (really interesting new
gene) Ligases (CRL’s). These families of ligases are the most studied yet are poorly understood. They
are not as frequently used in ubiquitin processes, albeit garner ubiquitin-ligase type activity [30]. There
are six types of CRLs organized based upon the substrate receptors utilized. The CRLs that are pertinent
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to Gam1 are Cullins 2 and 5, which utilize a BC box to recruit target proteins [30]. Gam1, however,
does lack two consensus aspects found in SOCS-box containing proteins: it does not contain a P/L rich
C-terminus, nor does it contain a highly conserved Cysteine residue at position 6 [24]. Bioinformatical
analysis conducted on a purported alpha helical region of Gam1 was overlaid an Elongin BC complexed
von Hippel-Lindau supporting the possibility that Gam1’s BC Box is indeed functional [36]. Further
analysis shows that there exists the possibility of Gam1’s C-terminal hydrophobic patch of residues to
interact with EloC in its hydrophobic pocket. The interaction between these proteins has been supported
by both in vivo and in vitro assays [24]. Currently multiple experiments have clearly demonstrated that
Gam1 functions as a mediator to eliminate the SUMOylation E1 via protein degradation. It has been
revealed that Gam1 also causes the loss of E2 within SUMOylation, by a yet unexplained mechanism.
No linkage has been established between Gam1 and E3 in SUMOylation.

1.1.3

SUMMARY
In essence, the focal point of the above introduction pertains to the initial discovery of Gam1,

whose function renders an environment more conducive for viral replication. Gam1 is the first viral
protein discovered to play a role in the global disappearance of SUMOylation. Viruses employ various
mechanisms, including manipulation of posttranslational modifications (PTM), in order to quell host
elimination. SUMOylation is one of such PTM pathways exploited by viruses, which has a known effect
on activating or de-activating gene production so that the virus can reproduce. The protein under
investigation Gam1 was the first viral protein discovered to globally inhibit SUMOylation, via the
degradation of E1 and E2 proteins in the pathway. SUMO-modified proteins have multifunctional
effects on protein stability, function, and also to affect either positively or negatively regarding
activation of genes. By impinging on host cell SUMOylation, Gam1 plays an essential role in viral
survival. In order for Gam1 to perform its function, it must interact with particular proteins and disrupt
6

the formation of protein complexes pertinent to SUMOylation. Collectively, these findings of Gam1
were the earliest ground breaking evidence showing one viral protein is capable of manipulating
important biochemical pathways, such as SUMOylation, in order to reproduce. While the disappearance
of E1 proteins in SUMOylation caused by Gam1 has been biochemically characterized, the exact
molecular details by which this occurs is still undetermined. The ultimate goal of this research is to
obtain a high-resolution crystal structure of Gam1. Determining the three-dimensional structure of
Gam1 is crucial in understanding its functions at a molecular level, particularly the mechanism by which
this gene regulates cellular SUMOylation enzymatic activity. In order to obtain a crystal structure, a
large amount of highly homogenous and functional Gam1 is critical, which is the main focus in this
chapter.

1.2

LONG TERM GOALS AND SPECIFIC AIMS

As mentioned in the introduction, Gam1 was the first viral protein discovered to globally inhibit
host SUMOylation via the elimination of SAE1/SAE2 and E2. However, the exact molecular
mechanism by which Gam1 alters SUMOylation is still unknown. The long-term goal of this research
is to determine the structure of Gam1 and understand its function within viral infection. Structural
elucidation of Gam1 will provide a better understanding of its function at the molecular level. Within
this dissertation, recombinant Gam1 has been cloned, expressed, and purified from bacterial expression
system. Furthermore, functional analysis has been carried out to verify the interaction between Gam1
and its cellular targets. These results will establish a foundation for the future structural determination
of Gam1 with or without the binding components. Two specific aims have been proposed in this
research to test the main hypothesis that Gam1’s function serves as a bridge from SUMOylation to
ubiquitination.
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Specific Aim One: To perform in vitro analysis of the interaction between recombinant Gam1
and SUMOylation pathway proteins. SUMOylation assays were utilized to analyze the association of
purified recombinant Gam1 and SAE1 and determine if SUMOylation is inhibited. Results obtained
from these experiments will show that recombinant Gam1 is not only properly folded but also has the
ability to bind SUMOylation proteins. This will clearly demonstrate one aspect of Gam1’s functionality,
which is the capability to interact with SUMOylation SAE1 directly. Compared to previous in vivo
experiments indicate SAE1 becomes targeted into Ubiquitin E3 ligase complexes through Gam1, here
we aim to show the in vitro direct interaction of SAE1 with Gam1, which will be coupled with future
structural analysis of the key region of the interface.
Specific Aim Two: To conduct in vitro studies of the interaction between Ubiquitination system
protein interactions and recombinant Gam1 to test its functionality. Similar biochemical techniques
utilized in Specific Aim One will aid in the analysis of interactions between recombinant Gam1 and
EloC, a Ubiquitin E3 ligase. BC-Box, a sequence required for the interaction with EloC binding was
found in Gam1 at its hydrophobic C-terminus. Results from this aim will provide direct evidence
whether Gam1’s BC-Box is functional. Gam1’s direct ability to interact with EloC will demonstrate the
key idea that Gam1 can navigate through both SUMOylation and ubiquitination. Future experiments
will include co-incubation with both SAE1 and EloC.
The Results obtained from both Aims will pave the way for future structural studies that will provide
essential information regarding the details of Gam1’s function as a bridge between these
abovementioned PTMs interactions. Information from the structure together with the biochemical
characterization will shed light on Gam1’s function in the viral replication cycle.
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1.3

MATERIALS AND METHODS

1.3.1

MOLECULAR CLONING OF GAM1 INTO AN EXPRESSION VECTOR(S)
Bacterial expression remains as one of the most popular methods to produce recombinant

protein; given its low cost, high yield, and relative ease of manipulation. One of the caveats however, is
the proper selection of a host and selection of a suitable promoter [37, 38]. All of the constructs selected
were for bacterial expression with different bacterial hosts and multiple vectors. The full-length gene
sequence was: amplified via PCR, restriction endonuclease digested, and ligated into an expression
vector(s) and transformed into competent bacterial cells. During the PCR primer design, expression tags
were added to either the N-terminal or C-terminus of Gam1 gene. These tags are for affinity purification,
enhancing solubility, assisted folding, and functional studies. Antibiotics were utilized to select
transformed cells. Ligated construct within the transformed cell was purified and verified by restriction
enzyme digestions and DNA sequencing.

1.3.1.1 POLYMERASE CHAIN REACTION AND CLONING
Polymerase chain reaction (PCR) is a widely used tool for molecular biology to amplify specific
DNA fragments using two unique primers specific for the targeted DNA (template) [39, 40]. Pairs of
primers were designed to target the 5’ and 3’ regions of the DNA sequence to be cloned. PCR primers
(table 1.1) with additional restriction enzyme sequences at the end were designed to amplify the gene of
Gam1 from a plasmid construct pSG9m (courtesy of Dr. Susana Chiocca) [41]. The final optimized
PCR reaction conditions utilized for each construct are listed in Table 1.1
Final PCR products were dual digested with respective enzymes (see table 1.1). The digested
products were gel harvested and ligated into the vector(s) following Invitrogen’s T4 DNA Ligase
protocol [42, 43]. Competent cells of E. coli strains of BL21(DE3) or Rosetta 2(DE3)pLysS were
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produced chemically following a lab protocol from Cold Spring Harbor [44]. The ligated products were
then transformed into either BL21(DE3) or Rosetta 2(DE3)pLysS competent cells following the
traditional 42°C heat shock method [44]. Ligated constructs were selected on ampicillin LB plates.
Individual bacterial colonies were picked, a glycerol stock was made, and subsequently stored in the 80°C. Purified plasmids from the glycerol stocks were verified by either PCR or restriction enzyme
digestion by the cloning enzymes. The constructs were also further verified by DNA sequencing (UTEP
Biology Core Facility). In these constructs affinity tags such as N terminal 6X, 10X His tag or Cterminal 6X His tags were incorporated during PCR, or acquired from the vector plasmids.
Furthermore, some of the vectors contain fusion tags, which facilitate protein folding, hence, increase
solubility and enhance further purification (described in detail later). Also, some cloning of Gam1 was
performed utilizing Invitrogen’s Gateway ® Directional Cloning system, which is based on DNA
recombination to directionally clone blunt end PCR products without the usage of restriction enzymes
[45, 46].

1.3.1.2 MOLECULAR CLONING IN MULTIPLE VECTORS
Five expression vector systems were selected with different tags for affinity chromatography
purification, as well as increasing the successful folding of the recombinant protein (See table 1.1). The
first one was a novel Gateway® cloning system from Invitrogen. In this system, the PCR product of
Gam1 is directionally recombined into an entry vector (pENTR/SD/TOPO), utilizing topoisomerase I
from vaccinia virus [47] without restriction enzyme digestion and ligation (refer to manufacturers
protocol). Correct entry colonies are screened via PCR and purified plasmid was used in the next
procedure. In the Gateway® system, Gam1 gene can be transferred into various destination vector
systems taking advantage of the site-specific recombination properties from bacteriophage lambda [48].
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The bacterial expression destination vector (pET-DEST42) was chosen because of its C-terminal 6X His
tag that can be used for purification purposes. The recombinant vector was subsequently transformed
into competent cells of E. Coli BL21(DE3) strain.
Concurrently, Gam1 was also cloned into another vector system pET-49b(+) (Novagen)
containing a Glutathione S-Transferase (GST) tag at the N-terminus, for purification and enhanced
solubility purposes (see table 1.1). GST is an enzyme found in both eukayotes and prokaryotes that
catalyzes the transfer of reduced glutathione (GSH) to a substrate [49]. Both the vector and the PCR
product of Gam1 were digested with restriction enzymes SpeI and XhoI and ligated by T4 DNA ligase
[© Life technologies] to produce an expression construct. The ligated construct was transformed into E.
Coli BL21(DE3) strain competent cells, individual colonies were verified by restriction enzyme
digestions and DNA sequencing. In Parallel, a C-terminal His tagged construct was generated, using the
pSG9m-Gam1 plasmid as the template to conduct PCR with the primers in table 1.1. The vector
selected was pET-30b(+) which has a 6X His tag at the C-terminus.
In order to optimize protein production using common codons in bacterial systems, the sequence
of Gam1 was codon optimized and synthesized de novo by Genscript ®. In addition, another vector
named pCold-Trigger Factor (© Takara, courtesy of Dr. Jianjun Sun, Department of Biological
Sciences, UTEP) was utilized to express the codon optimized Gam1. (TF) is a prokaryotic ribosome
associated [50, 51] with a cold shock chaperone of 48kDa that helps in polypeptide folding at low
temperatures to reduce the chances of forming mis-folded and insoluble proteins [52, 53]. As a native
product from prokaryotes, TF is highly expressed in E.coli using the strong cspA promoter. In addition,
the pCold-TF vector contains: translation enhancing elements, an N terminal His-Tag before TF, and
multiple cleavage sites to separate from the target protein. Both pCold-TF vector and Gam1 were
digested with restriction enzymes NdeI and HindIII and ligated by T4 DNA ligase (© Life technologies)
to produce a construct (Table 1.1). The clones were screened and confirmed by restriction enzyme
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digestions and DNA sequencing. Gam1 was also cloned into pCold1 (© Takara, courtesy of Dr. Jianjun
Sun, Department of Biological Sciences, UTEP), which maintains the same elements as N-pCold-TF,
however lacking the TF at the N-Terminus of the recombinant protein. Digestions and ligation reactions
were performed following the methods listed above.
In addition, Gam1 was also cloned into a modified pCold-TF vector (referred to as C-pCold-TF).
In this modified vector, one of the three cleavage sites as well as the N-terminal 6X His tag were deleted
(performed by Dr. Jianjun Sun, Department of Biological Sciences, UTEP). Primers were designed with
an additional C-terminal 6X His tag after the recombinant Gam1 gene, for purification purposes. This
construct with a C-terminal 6X His tag was designed to ensure full-length expression of recombinant
Gam1. C-pCold-TF and PCR product of Gam1 were digested with NdeI and EcoRI and ligated by T4
DNA ligase (© Life technologies) to produce a construct (Table 1.1).

Table 1.1
Clone

pET30b+Gam1-His

Primers and PCR Settings For Gam1 Amplification

Initial
Denaturation

Denaturation

Annealing

Extension

Final
Extension

Time (s)

Time (s)

Time (s)

Time (s)

Time (s)

@ Temp

@ Temp

@ Temp

@ Temp

@ Temp

Primers:
Sense:
5’ CGCCCATATGGCCCGCAACCCATTCGCATGTTCCCT -3’
NdeI
Antisense 1:
5’- CGCGCTCGAGATGATGATGATGCAGAGAATGGTAGGGGTG -3’
XhoI
94 C @ 60 s

94 C @ 10 s

62 C @ 20 s
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65 C @ 120 s

65 C @ 600 s

pDEST42Gam1-His

Primers:
Sense:
5’- CACCATGGCCCGCAACCCATTCCGCATGTTCCCTG -3’
CACC overhang for Invitrogen Gateway ® cloning
Antisense:
5’- AGCTGCGGAGCGACCTTCAATCAGAGAATGGTAGGGGTGGTGC -3’

94 C @ 60 s
pDEST42His-Gam1
(the PCR
was done in
three steps)

94 C @ 10 s

68 C for 20 s

65 C @ 120 s

65 C @ 600 s

Primers:
Sense #1
5’- GCGGCTATTGAAGGTCGCGCCCGCAACCCATTCCGC -3’
Sense #2
5’- CACCACCACCACCACCACCACCACTCCGCGGCTATTGAAGGTCGC- 3’
Sense #3
5’- CACCATGGCAGCAGCACACCACCACCACCACCACCACCAC -3’
CACC overhang for Invitrogen Gateway ® cloning

Antisense:
5’- TTACAGAGAATGGTAGGGGTGGTGCCGAGACCCGAGTCC -3’
Stop codon
94 C @ 30 s
pET49b+GST-Gam1
(the PCR
was done in
two steps)

94 C @ 10 s

68 C @ 20 s

65 C @ 51 s

Primers:
Sense #1
5’- GGTAGTATTGAAGGTCGCGCCCGCAACCCATTCCGC -3’
Sense #2
5’- GCGCACTAGTGGTGGTGGTAGTATTGAAGGTCGCGCC -3’
SpeI
13

65 C @ 600 s

Antisense:
5’- GCGCCTCGAGTTACAGAGAATGGTAGGGGTGGTG -3’
XhoI

94 C @ 30 s
pCold-HisTF-Gam1

94 C @ 10 s

68 C @ 20 s

65 C @ 51 s

65 C @ 600 s

De novo synthesized construct (Genscript) in pUC57 digested with 5’-NdeI and 3’
HindIII

pColdIGam1

De novo synthesized construct (Genscript) in pUC57 digested with 5’-NdeI and 3’
HindIII

pCold-TFGam1-His

Primers:
Sense
5'GCGCTACATATGGCTCGTAATCCGTTTCGTATGTTTCCGGGCGACCTGCCG
TACTACATGG -3'
NdeI
Antisense
5'
GGTCGAATTCTTAATGATGATGATGATGATGGCGACCTTCAATCAGCGAAT
GATACGGATGAT 3'
EcoRI

98 C @ 30 s

98 C @ 10 s

66.1 C @ 15 s
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72 C @ 5 s

72 C @ 600 s

1.3.2

EXPRESS TARGET PROTEIN:
E.coli expression systems were utilized to produce large quantities of Gam1 due to its low cost,

fast growth, and easy manipulation. BL21(DE3) and Rosetta 2(DE3)pLysS cells (both from Novagen)
are modified E.coli bacterial strains that have T7 promoter region, which can produce more proteins
than normal bacteria. Rosetta 2(DE3)pLysS strain is derived from BL21(DE3). Both can effectively
express protein due to the absence of two genes, lon and ompT, that code for two key proteases, which
degrades misfolded protein and removes extracellular proteins, respectively [54]. Reduced protease
degradation and tight regulation of expression make these strains optimal for E. Coli production.
Additionally, Rosetta 2(DE3)pLysS contain tRNA’s for seven rare bacterial codons, which will facilitate
the expression of eukaryotic proteins [55, 56]. Moreover, the addition of T7 lysozyme in this strain helps
suppress basal expression levels of the T7 RNA Polymerase before the induction by IPTG, preventing
leaky expression of target protein.
For expression trials, a few of the clones were grown in media maintaining the same conditions
to determine the most suitable clone (demonstrating the best expression) for large-scale purification.
Once the best clone was selected, further small-scale expression trials have been carried out to optimize
conditions relating to protein expression: such as bacterial growth, temperature for induction, and
amount of time for post-induction expression. After the optimal conditions have been established, largescale expression were conducted to purify the target protein to high homogeneity utilizing various
chromatographic techniques.
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1.3.2.1 PROTEIN EXPRESSION FOLLOWING TRADITIONAL BACTERIAL GROWTH
The constructed plasmids control the expression of nascent protein under the induction with
IPTG. Multiple optimization trials were performed including differences in media composition,
temperature, optical density (OD) before induction, IPTG concentration, and time post induction to
establish the optimal conditions for protein expression. An auto-induction system (MagicMediaTM
Medium, see protocol © Life technologies) was also tried. Constructs including GST-Gam1, pET30b(+), and pET-DEST42 were expressed under the optimized condition described below.
Transformants of GST-Gam1 in pET-49(b)+ (constructed in house) were grown in 100 μg/mL
ampicillin LB liquid media at 37°C agitating at 220 rpm until an OD600 of 0.8 is reached. Then the
culture was immediately induced with 1 mM IPTG and incubated four hours at 30°C with 200 rpm
agitation. The cells are harvested by centrifugation at a speed of 5000xg and the pellets are resuspended in lysis buffer (50mM HEPES pH 7.5, 10mM MgCl2, 150mM NaCl, 0.02% NaN3 and 1mM
phenylmethylsulphonyl fluoride PMSF). The re-suspended pellets were then subjected to freeze-thaw
three times to lyse the cell. Lysozyme was added to final concentration of 0.5 mg/ml to assist in cell
lysis. Lysozyme is an enzyme that digests the peptidoglycan of the rigid cell wall of E. coli, leaking the
cellular contents including the expressed target protein. The cell lyses are then centrifuged at a high
speed of 35,000xg at 4°C for 40 minutes to remove cell debris, large cellular organisms and un-lysed
cells. To verify protein production, SDS polyacrylamide gel electrophoresis (SDS-PAGE) was used.

1.3.2.2 COLD INDUCTION PROTEIN EXPRESSION
Conditions for protein expression were optimized with the C-pCold-TF, which were
subsequently utilized for all future expression protocols. In contrast to expression protocols mentioned
above, the pCold-TF cultures were grown to an OD600 of 0.6, at which point agitation was stopped and
temperature was dropped to 16°C for 1 hour. Culture was then induced with 0.1 mM IPTG and
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maintained at 16°C for 14 hours. Cells are harvested by centrifugation at 5250xg for 40 minutes at 4°C
and the pellets are re-suspended in lysis buffer (50mM Tris-Cl pH 7.5, 300mM NaCl, 0.02% NaN3,
1mM PMSF, and 10mM imidazole) and is subsequently treated with freeze-thaw process with lysozyme
(0.2 mg/mL) and harvested as described above. Centrifugation at a high speed of 35,000xg at 4°C for
40 minutes (repeated twice) removes cell debris, large cellular organisms, and un-lysed cells. Cleared
lysate is then used for protein purification.

1.3.3

PROTEIN PURIFICATION TRIALS
Purification of recombinant protein is essential for usage in biochemical characterization.

Traditional methods of purification are largely based on the downstream usage of the target protein,
which include: affinity chromatography respective to the expression clones affinity tag, followed by
refinement chromatographic techniques such as ion exchange, and size-exclusion to reach high
homogeneity. In affinity chromatography, the properties of the target recombinant protein are well
defined (such as an additional 6X-His tag) that can be exploited in the purification process. This will
result in separation from other non-specific proteins yielding a relatively pure protein. Immobilized
metal ion affinity chromatography (IMAC) is based on the affinity of the amino acid Histidine for
bivalent metal ions, such as cobalt, copper and nickel[57]. GST tagged proteins follow the same
premise of affinity purification by both increasing the solubility of the target protein as well as being
captured via immobilized glutathione while impurities remain unbound [58]. Refinement techniques
such as ion exchange chromatographies take advantage of the difference in protein charge at different
pH. This is based on the electrostatic attraction and repulsion between the immobilized charged
molecules and the charge on the target protein [59]. There are two types of exchange columns (cation
and anion) that can be used based on the charge on the protein. Negatively charged proteins interact
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with positively charged ions in anion exchange chromatography (AEC). The reverse is true for
positively charged proteins.
Gel filtration, also referred to as size exclusion chromatography is based on the molecular weight of the
protein. The matrix of the column contains tiny pores, which freely interact with smaller weight
molecules, whereas larger molecules do not enter the pores and are thus excluded in decreasing
molecular size [60]. Therefore, samples applied to the SEC will elute larger proteins first and retain
smaller proteins within the matrix longer.
Since the constructed clone(s) contain multiple affinity or solubility factors, such as 6X Histidine
and GST, Nickel-NTA affinity chromatography as well as purification via the GST fusion Tag was used
to purify recombinant protein. Purifications were performed using either a HisTrap HP or GSTrap FF
(both from GE) to identify the binding of the recombinant protein and purify from non-specific
contaminating proteins. Refinement chromatographic techniques included: (HiPrep Sephacryl s200,
HiLoad 26/600 Superdex 200) as size exclusion, HiTrap Heparin HP as a cation exchanger, and HiTrap
Q HP anion exchanger.
GST-Gam1 constructs were initially purified using following manufacturer specifications.
Lysate was prepared as mentioned in the previous section, and the supernatant was passed through a
0.45 μm filter (Millipore) and then loaded onto a 5 mL GSTrap FF (GE Life Sciences), equilibrated
with buffer A (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) adjusted to pH 7.4.
The column was washed with 50 mL buffer A to remove nonspecifically bound proteins. Target protein
was then eluted with buffer B (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 10 mM
Glutathione, and 1 mM EDTA) pH 8.0. Given that the binding efficiency to the column is flow rate
sensitive, slow flow rate trials at a sample application of 0.1 mL/min were attempted Figure 1.3.2.
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His-Hitrap HP column was purchased from GE healthcare Life Science. HisTrap HP columns contain
cross-linked sephorase beads with a chelating group attached to it. Histidine has an affinity towards
Ni2+ and 6X His will have increased affinity for Ni2+. It has been found that Histidine tagged proteins
bind strongly with Ni2+ thus allowing for affinity chromatography.
Purification of constructs containing a 6 or 10X His tag were conducted on Nickel columns.
Small scale Gravity flow affinity chromatography was used to optimize the purification conditions. 5
mL Ni-NTA agarose beads (Qiagen) suspended in a gravity column was equilibrated with 25 mL of
binding buffer (50 mM Tris pH 7.5, 300 mM NaCl, 10 mM Imidazole, 0.02% NaN3, and 1mM DTT or
50mM HEPES pH 7.5, 100mM NaCl, 10 mM MgCl2, 20 mM Imidazole, 1 mM PMSF, and 0.02%
NaN3). 50 mL cell lysates were filtered by 0.45µm filter and loaded onto the column via gravity flow
and any unbound sample was washed out with the same buffer, while allowing only His tagged protein
to bind to the column. The flow through was collected in a separate sample tube. Elution’s were
performed by utilizing step gradient from 20-250 mM imidazole obtained by mixing the binding buffer
above with different percentage from a stock elution buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1M
imidazole, 0.02% NaN3 and 1mM DTT, or 50mM HEPES pH 7.5, 100mM NaCl, 10 mM MgCl2, 1 M
Imidazole, 1 mM PMSF, and 0.02% NaN3). Optimal washing (125mM imidazole) and eluting (210 mM
imidazole) conditions were established and used in chromatographic purification using AKTA FPLC
(Amersham) and 5mL His-Hitrap column (GE). 90 to 100 mL cell lysate was filtered and loaded to the
column, followed by washing with 30 mL 125 mM imidazole buffer and eluting at 15 mL 210 mM
imidazole elution buffer. Further chromatographic techniques such as Ion exchange, and Size exclusion
were utilized for all constructs. Salt precipitation with ammonium sulfate was also tried to remove
contaminants from the target protein. The reasoning was that the ionic strength of the target protein
would be different than that of the contaminants, which could be later used for other chromatographic
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techniques Figure 1.3.4. Affinity purified Gam1 was subjected to both ion exchange and size-exclusion
chromatography for further purification.
The eluent from affinity purifications were loaded onto a SEC (HiPrep Sephacryl S200)
equilibrated in (50 mM HEPES pH 7.5, 10 mM MgCl2, 150 mM NaCl, and 0.02% NaN3) (Figure 1.3.5).
All other SEC experiments were on (HiLoad Superdex 26/60 200) equilibrated with (25mM Tris pH 8.0,
150mM NaCl, 0.02% NaN3). Gam1-GST constructs as well as Gam1-pET vectors were run on cation
exchange with HiTrap SP FF was equilibrated with Buffer A (50 mM HEPES pH 7.5, 10 mM MgCl2,
150 mM NaCl, and 0.02% NaN3). Protein was eluted with a linear gradient with Buffer B (50 mM
HEPES pH 7.5, 10 mM MgCl2, 1 M NaCl, and 0.02% NaN3) HiTrap Heparin HP equilibrated in
Binding buffer (10 mM Na2HPO4, and 0.02% NaN3). Elutions were performed with a linear gradient
using elution buffer (10 mM Na2HPO4, and 0.02% NaN3, 1M NaCl).
The eluent from HiLoad Superdex 26/60 200 was loaded onto IEX (HiTrap Q HP, GE) preequilibrated in Buffer A (50 mM Tris pH 8.0, 100 mM NaCl, 0.02% NaN3), and eluted with Buffer B
(50 mM Tris pH 8.0, 1 M NaCl, 0.02% NaN3, and 1mM DTT) using a linear gradient.
All samples were analyzed for purity on an SDS-PAGE. Samples were prepared with 4X SDS PAGE
dye then heated at 100°C for 5 minutes and run on a 10% SDS PAGE stained by Coomasie Blue. Silver
staining technique was also utilized to determine the purity of MCP. To determine Protein concentration
a standard protein assay kit using BSA (©Thermo scientific) as a reference was utilized.

1.3.4

BIOCHEMICAL CHARACTERIZATION

1.3.4.1 DLS IN GAM1 CHARACTERIZATION
Dynamic light scattering (DLS) is a widely used technique to determine the size, shape and
distribution of particles. DLS utilizes a monochromatic laser beam whose wavelength changes when it
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passes through a solution with particles in random motion (Brownian motion). This change of
wavelength is correlated to the largest dimension size of the particle. When a particle is rotating very
fast in a solution, the shape of the particle can be assumed to be spherical with the longest dimension of
the molecule considered the diameter. Therefore, DLS can provide an estimate of the protein size. For
instance, DLS can be used to characterize protein interactions with a visible shift in the size distribution.
This is very useful when investigating multimeric proteins as well as other macromolecular interactions.
If the protein is temperature sensitive, or has an increased propensity towards aggregation, DLS may be
utilized to analyze the size difference under various conditions. Therefore, DLS can be also used to
monitor particle size distribution and species, such as aggregation formation, in real time. In addition,
the newer models of DLS instruments can also measure surface charge potential of the protein. This
surface charge measurement is very useful for refinement purification procedures, providing insight as
to what type of ion exchange chromatography techniques to further purify your target protein. DLS is a
really useful technique that does not waste sample, measures in real-time, and does not require large
concentrations of sample.
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Fig 1. 1 Schematic representations of how scattered waves are correlated to particle distribution using
dynamic light scattering detection. Adapted from © Copyright Particle Sizing Systems
DLS measurements of Gam1 in N-pCold-TF and C-pCold-TF were collected. The size
distribution helped to distinguish between aggregates and potentially native Gam1. The zeta potential as
determined by DLS using a Zetasizer nano ZS (©Malvern) instrument revealed that Gam1 has a slightly
negative surface charge.
3 mg/ml Gam1 concentration was used for DLS analysis. 10µl of sample was diluted with 990µl of
buffer composed of 25mM Tris pH 8.0, 150mM NaCl and 0.02% NaN3. Manual settings were set up to
collect from 12-20 measurements every 10 seconds. The laser light source utilizes a wavelength at 633.
The same instrument was used to measure the surface charge of Gam1 in the aforementioned constructs.
A cuvette containing electrodes at both ends was used to collect data. The premise is based on the
charge of the sample, which become attracted to the electrodes with the opposite charge. The zeta
potential is a measure of the velocity at which the particle moves (electrophoretic mobility).
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1.3.4.2 IN VITRO SUMOYLATION ASSAYS IN GAM1 CHARACTERIZATION
Gam1’s ability to globally inhibit the SUMOylation pathway has been established using in vitro
assays, therefore highly pure Gam1 ~90% at a concentration of 0.5 mg/mL was sent to Dr. German
Rosas-Acosta for SUMOylation inhibition assays to verify the previously described disappearance of E1
and E2 from the SUMOylation pathway. In vitro SUMOylation reactions were carried out following an
established protocol [61], with minor modifications. Brieﬂy, 2 µL of 35S-methionine labeled influenza
virus NS1, a SUMOylation target [62-64], produced by a coupled transcription/translation system
(Promega Corp., Madison,WI) was incubated with various amounts of recombinant pCold-TF-Gam1,
200 ng GST-SAE2/SAE1, 200 ng GST-UBC9, and 3.4 µg of His-SUMO1 in a ﬁnal volume of 26 µL
solution containing 50 mM Tris pH 7.4, 2.5 mM DTT, 2 mM ATP. All incubations were performed at
37°C for 90 min. The positive control contains all the components listed above without any pColdGam1. As negative control, a mock protein expressed in the same pCold-TF vector system was used to
show the TF tag does not affect the in vitro SUMOylation. Another control of 100% SUMOylation
abolishment was obtained by adding an afﬁnity-puriﬁed catalytic domain of the yeast SUMO protease
Ulp1 (Ulp1403–621) [21] 60 min after the initial reaction began. All reactions were quenched by the
addition of 4× SDS-PAGE sample buffer (50 mM Tris pH 6.8, 10% glycerol, 4% SDS, 0.01%
bromophenol blue, 2% B-mercaptoethanol). Samples were then boiled for 4 minutes, run on SDS–
PAGE, and transferred to Immobilon-FL (0.45 m) membranes (Millipore Corp., Bedford, MA).
Membranes were developed by autoradiography using a Personal Molecular ImagerTM and Quantity
OneTM software (both from Bio-Rad Laboratories) or by immunoblotting using IRDye-conjugated
secondary antibodies and infrared fluorescence imaging using an Odyssey CLx imaging system (both
from Li-Cor Biosciences, Lincoln, NE). Statistical analyses were performed using GraphPad Prism,
utilizing unpaired single tailed t-tests with Welch correction.

23

1.4

RESULTS AND DISCUSSIONS

1.4.1

CLONING OF GAM1
Initial Gam1-GST construct was obtained from Dr. Susana Chiocca, our international

collaborator. All pET vector constructs were generated from the plasmid provided by Dr. Chiocca.
Amplification of the Gam1 gene for cloning into the aforementioned constructs was performed with a
Long Amp PCR kit (© New England Biolabs) (Fig 1.2). Cloning was by either conventional restriction
endonuclease reactions or by using the Invitrogen Gateway (©Life technologies) cloning system. The
selected Gateway cloning system utilized directional cloning as a method to perform recombination
reactions known as LR recombination. This entry vector (pENTR/SD-TOPO) carries the gene, which is
then swapped into an expression vector suitable for bacterial expression. Re-cloning into pET-49b(+)
again with the aforementioned kit was unsuccessful after multiple trials. Furthermore, DNA sequencing
revealed amino acid mutations that would potentially alter Gam1’s function. Conditions used for pET30b(+) cloning resulted in mutations within the gene of interest; therefore, further expression
experiments were not pursued. No suitable constructs were produced (Fig 1.3), therefore multiple
efforts to troubleshoot the cloning was pursued. After many trials, a handful of clones were produced
after following a ligation reaction, which was immediately tested for expression (Fig 1.4). Due to these
issues, it was decided to de novo synthesize a bacterial expression codon optimized Gam1 from
Genscript. One optimized for cloning into N-pCold-TF and another with an additional 6X His tag at the
C-terminus of the Gene for cloning into C-pCold-TF. These clones were sent in pUC57, cloned with
NdeI and HindIII for N-pCold-TF; and NdeI and EcoRI for C-pCold-TF. Restriction enzyme reactions
were performed from the Genscript clone and ligated into the above-mentioned N-pCold-TF vector.
Primers listed in table 1.1 were utilized to amplify Gam1 gene and an additional 6X His tag to generate
C-pCold-TF. The expression vectors and Gam1 were successfully cloned using the conditions
mentioned above. Reactions performed in the cloning process the digested insertion and vectors
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required purification. This was carried out via agarose gel electrophoresis. All products were ligated by
T4 DNA ligase. Constructs were then transformed into variants of BL21 (DE3) (BL21 codon+, or
Rosetta 2(DE3) pLysS). The plasmids of individual bacterial colonies were purified (Qiagen miniprep
kit), and subsequently digested with the restriction enzymes utilized for each respective construct
(pET49 and C-pCold-TF). C-pCold-TF with bands at 5.7kb (vector) and ~900 bp (Gam1) demonstrate
the successful cloning of Gam1 (Fig 1.5). DNA sequencing performed on pET-DEST42 demonstrated
an amino acid mutation at the C-terminus of Gam1 (Data not shown). pCold-TF constructs were found
to have no mutations, thus cloning was successful.

Amplified PCR products or digested from pUC57 from above explained PCR and digestion
experiments Table 1.1 and both pColdTF vectors were cut with the abovementioned pair of restriction
enzymes and was cloned into pColdTF by T4 DNA ligase. Transformed product from the reaction was
plated on selectivity plates (Fig 1.6) and the resulting plasmid was purified from BL21 (DE3) cells. To
verify the successful insertion of recombinant Gam1 into the vectors, restriction enzyme digestions were
performed. Results obtained demonstrated two distinct DNA fragments at the expected sizes of 5.7Kbp
and ~900 bp Fig 1.5 when run in an agarose gel. Furthermore, the recombinant DNA was verified by
DNA sequencing.

1.4.2

PROTEIN EXPRESSION
The construct provided by Dr. Chiocca (pSG9m) was used for cloning purposes into three pET

vector systems mentioned in 1.3.1.2. An uninduced control was utilized to compare with the induced
protein, and both were run on the gel (Fig 1.4). A protein band above the 50 kDa marker was apparent
in the induced sample, yet not visible in the uninduced sample. Small-scale expression trials for pET
30b(+) as mentioned in section 1.2.1.2 was performed and low detection and non-specific protein was
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produced (Fig 1.7-.8). Large-scale expression attempts included the usage of auto-induction low
temperatures, differences in expression time and the target protein was determined to be insoluble and
was being removed in the centrifugation step as an inclusion body. In an attempt to improve protein
production, these constructs were tested in Rosetta 2 pLysS(DE3) [65] (EMD Millipore) that contains
plasmids encoding tRNAs for rarely used bacterial codons [56]. However, no improvement of Gam1
expression was observed. Furthermore, cloning into pET DEST 42 produced mutations within the gene
leading to the abandonment of these two constructs. No further experiments were attempted (results not
shown).
Difference in pCold the N-pCold-TF constructs were grown at 37°C 220 rpm to an OD600 of 0.8 in LB
medium containing 100 μg/mL ampicilin, culture was then induced with 1 mM IPTG and allowed to
cool for 30 minutes at room temperature. After 30 minutes the culture was refrigerated at 16°C for an
additional 18 hours 200 rpm. After 18 hours of incubation at 16°C. Individual sequence verified
colonies were grown and induced with IPTG (1mM) to verify the expression of target N-pCold-TF (Fig
1.9). As shown in Fig 1.9, in comparison to the control E. Coli BL21 (DE3) cells, N-pCold-TF+Gam1
generated a protein band above the 75 kDa molecular weight marker. This size (79kDa) corresponds to
the TF-Gam1 fusion construct. In order to optimize protein production, different induction conditions
were tested (Fig 1.10). Protein in excess was produced in both conditions; therefore, the lower IPTG
condition was selected for further large-scale expression. The successful expression of recombinant
Gam1 can be attributed to the codon optimization, coupled with the usage of TF in assisted protein
folding. This compared to previous expression constructs mentioned above yielded viable protein that
was clearly not seen in control E. Coli. After successful small-scale protein expression trials, large-scale
protein expression with optimized induction conditions was performed. Although pCold-His-TF-Gam1
construct yielded abundant protein (Fig. 1.9-10), significant amounts of lower molecular weight TFGam1 protein were observed after several steps of chromatographic purification. These lower molecular
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weight TF-Gam1 can be either incomplete translation products of TF-Gam1 or degraded TF-Gam1 from
the C-terminus (Fig 1.11). Therefore, in order to purify full length Gam1 from affinity chromatography,
the 6xHis tag at the N-terminus was removed and added to the C-terminus of the construct. The same
conditions mentioned above were carried out for the expression of C-pCold-TF and pCold1-Gam1. You
can see in (Fig 1.12) that recombinant Gam1 is being expressed, albeit is seen in the inclusion fraction.
In the case of C-pCold-TF this was due to the incomplete extraction from the whole cell lysate, which
was corrected with the addition of Lysozyme. In the Case of pCold1-Gam1, this was not improved
suggesting an insoluble recombinant Gam1 protein (Fig 1.13).

1.4.3

PURIFICATION
Initial purification trials were carried out using GST-Gam1 as detailed in 1.3.3, Gam1 inducible

expression was achieved (Fig 1.4) albeit protein would always retain at least two other protein
contaminants (Fig 1.14-17). Multiple efforts utilizing various chromatographic techniques were carriedout. Three major contaminants were repeatedly produced in protein expression and could not be
removed from Target GST-Gam1 construct. This could be a result of endogenous proteins expressed in
bacteria, which form an interaction with the fusion protein. During expression trials, one of the major
contaminants was GST alone, which was only removed by size exclusion chromatography. The purest
protein obtained was via size exclusion (Fig 1.17), albeit protein amount was insignificant and still had a
contaminant immediately below the target. Therefore re-cloning into a different expression vector was
pursued.
The presence of 6X-His tag at the N or C-terminus of the recombinant Gam1 facilitates the
possibility of obtaining relatively pure protein via Nickel NTA column. Given that Nickel is one of the
most widely utilized bivalent metals for purifying His tagged proteins [57, 66, 67]. Nickel has been
demonstrated to have a high affinity towards histidine residues, however, it has a strong tendency to
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bind non-specific proteins [68] if the target protein is low in expression or has the affinity tag hidden.
Earlier pET constructs exhibited non-specific protein interactions when purified solely using Ni affinity,
and attempts to segregate the non-specific proteins prior to affinity using ammonium sulfate
precipitation (Fig 1.18) also proved useless. In order to remove this possibility of nonspecific
interactions, 10mM Imidazole was added to the binding buffer. Trial purifications with gravity flow
affinity chromatography (Ni-NTA beads) utilizing step gradient elutions to determine the optimal wash
and elution of target protein was carried-out. SDS-PAGE analysis demonstrated that recombinant TFGam1 represented approximately 40% of soluble proteins in the crude sample before purification (Fig.
1.19). After washing with 40mM, 60mM, 80mM, and 120mM, imidazole concentrations and eluting
with 200mM Imidazole, greater than 70% purity Gam1 was obtained (Fig 1.20). Approximately 4 mg/L
was generated of target protein for downstream chromatography. From the gravity flow experiments
conditions were utilized to perform large-scale purification trials using HisTrap HP columns as a twostep gradient elution. Optimization dependent on the amount of imidazole to utilize for washing out
contaminating bands was varied from 100-200 mM and elutions from 200-400 mM. The ideal
conditions were determined to be with washes 125 mM and elution at 210-220 mM imidazole
respectively. Lysate loading capacity was determined to be 0.6L for pCold-TF (With N-terminal His)
N-pCold-TF and 2.5L for pCold-TF (with C-terminal His) C-pCold-TF. Later experiments with pColdTF utilized Buffer A (Binding Buffer) was 50 mM Tris pH 7.5, 300 mM NaCl, 10 mM Imidazole, and
0.02% NaN3. Buffer B (Elution Buffer) was. C-pCold-TF was optimized on the HisTrap HP column
with ideal washing conditions at 190mM, and elution at 400 mM (Fig 1.21). This was later determined
to be too high a concentration; therefore, washing conditions were reduced to 120 mM and elutions at
200 mM Imidazole, respectively.
Most of the contaminants were removed with 125 mM, with protein purity after one step
estimated at about 70%. Further purification using size exclusion chromatography (SEC) yields a
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protein with a purity exceeding 80% as determined by Coomassie blue stained SDS-PAGE (Fig 1.2223), effectively removing the smaller contaminants and the majority of the 52 kDa band corresponding
to trigger factor alone. BSA standards were utilized to calibrate the elution volumes correlated to the
size of the protein. SEC also provides a profile of different Gam1 forms in the sample: aggregated,
dimeric and monomeric (Fig. 1.23). It was determined that monomeric TF-Gam1 would elute at ~185
mL. Three distinct peaks are observed in the SEC profiles (Fig 1.23) where in the cold temperature
optimized purification a larger peak is observed at the monomeric size of TF-Gam1, as compared to the
room temperature pH’ed buffers. The fraction corresponding to the monomeric TF-Gam1 was collected
and utilized for biochemical characterization. To determine the purity of TF-Gam1 after SEC, the
samples were run in a SDS PAGE (Fig 1.22 & 1.23), demonstrating protein purity above 85%. Gam1
was further purified utilizing ion exchange chromatography (IEX) on HiTrap Q HP (GE), which
produced a protein with purity exceeding 90% (Fig 1.24).

1.4.4

CHARACTERIZATION
DLS measurements were utilized to track the forms of recombinant Gam1 obtained from

purification techniques. These measurements proved to be complimentary to the SEC profiles in
helping assess the quality and status of recombinant TF-Gam1. The first elutions from SEC represent
protein that elute in the exclusion volume of the column. These represent aggregates of recombinant
Gam1, and when measured using DLS display a hydrodynamic diameter greater than 40 nm is size with
an average typically 53 nm. The dimeric form of Gam1 generally gave measurements between 16-30
nm, with an average approximately at 23 nm. Finally, the monomeric form of TF-Gam1 would be about
9-13 nm, with the highest representation being around 10 nm. Based on SEC and DLS profiles, three
factors have been found to be critical to increase the level of monomeric Gam1. First, it is critical to
adjust buffers’ pH at 4°C because the small pH difference caused by temperature displayed a dramatic
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effect on obtaining monomeric TF-Gam1. Secondly, the addition of DTT to the purification buffers,
clearly demonstrates a shift towards monomeric Gam1 while the dimeric and aggregate forms are
decreased (Fig. 1.23,1.25). Zeta potential measurements were taken to assess the charge on the surface
of TF-Gam1, which further verifying that the overall charge was indeed negative (Fig 1.26). Reducing
environment could have decreased the formation of false intermolecular disulfide bonds that can cause
dimerization or aggregation [69, 70]. A dramatic effect concerning DLS measurements at different
temperatures was also observed when characterizing the sizing profiles of Gam1 samples at room
temperature as compared to 4°C, with TF-Gam1 increasing in size over time at room temperature. The
effect of salt on polydispersity was also tested utilizing different salt concentrations ranging from 100-1
M NaCl. The sizing profiles saw negligible differences after the addition of 400 mM NaCl, where the
peak intensity shifted to a higher hydrodynamic measurement (Fig 1.27).

1.4.5

DISCUSSION

1.4.5.1 CLONING
Given that earlier trials of PCR amplification were carried out utilizing Long Amp PCR kits
(NEB; based on the Taq DNA polymerase), mutation rates are more frequent than other polymerases
and have been shown to also cause frame-shifts [71, 72]. To avoid these issues, the Phusion High
Fidelity (Finnzymes), which has a mutation rate fifty times lower than Taq [73, 74]. Moreover, cloning
issues coupled with the inability to produce viable protein for structural studies lead the decision to
clone using a novel system know as Invitrogen’s Gateway ® Directional Cloning system. This system
was advertised to have a cloning efficiency higher than 90%, without the need for traditional Restriction
enzyme digestions and ligations. In practice however, over 80 clones were screened using this system
and the success rate was determined to be less than 10%. Additionally, verified clones that were later
expressed never gave a soluble protein. Due to the difficulties encountered, coupled with the expense
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associated with the system it was decided to move away from directional cloning. Gam1 was codon
optimized for bacterial expression, and cloned into an alternative vector system, the pCold Trigger
Factor (TF) that has a bacterial chaperone TF to assist the folding. The first sequence verified and
viable protein expression was in the pCold-TF vector systems. This is a result of the fact that the vector
contains a fusion protein that aids in the folding of Gam1.

1.4.5.2 PROTEIN EXPRESSION

Protein expression in early pET constructs had two key problems: 1) there was little protein in
comparison to other major contaminants, and 2) protein expression was not observed at all. In regards
to the first issue, of protein expressed in E.coli is quite common [75, 76]. There are various factors that
lead to the insolubility of the recombinant protein. One of which could be the fact that the Gam1
construct provided by Dr. Chiocca was produced from Wild type Gam1, meaning it has codons that are
rarely seen when trying to express in E.coli.. Secondly, and most importantly, Gam1 carries out it’s
biological function by interacting with proteins in the SUMOylation and ubiquitination pathways and
could result in its interaction with proteins produced in bacteria. This would account for the inability to
separate Gam1 from contaminants. As mentioned above, Gam1 was expressed in different strains of E.
Coli to try to relieve expression issues, which have been shown to improve protein production [77, 78].
The pET vector systems utilized were under the control of T7 promoter systems. One of the major
limitations using these strong promoter systems is the fact that recombinant protein produced may not be
in its native conformation, which will shift its susceptibility to be isolated into the insoluble pellets
(inclusion bodies) [79]. Furthermore, high levels of protein production can at times account for more
than 40-50% of the total cellular proteins. This will call for high quantities of mRNA, which can lead to
elimination of the ribosomes and ultimately lead to cell death. These strong promoter systems also have
been known to have leaky expression [80] that may lead to the instability of protein expression [81].
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Also, Gam1 contains a hydrophobic region at the C-terminus, which is purported to be the location
where EloB/C binds. Without this interaction, Gam1 could potentially aggregate to protect that region.
Another possibility is that protein expression with IPTG can produce large quantities of exogenous
protein (toxic to the bacteria) and may be targeted for degradation. In tune with this, the large amounts
of protein generated could also outpace the native folding process, leading to accumulation of unfolded
protein as aggregates. Therefore, co-expression with solubility enhancers was utilized to resolve these
issues. Molecular chaperones or solubility enhancers have been thoroughly investigated [82] and have
resulted in the enhanced expression of soluble target protein. Moreover, the expression of protein at
lower temperatures [83] can improve solubility of E. Coli produced proteins, however the behavior of
proteins various from case to case and remain insoluble [84] or difficult to purify such as with Gam1. It
is also common to express in systems that utilize promoters that generate protein at lower temperatures
[85]. One of the well-characterized and utilized cold shock promoters is the CspA from E. Coli [86-88].
Many times the problem is not actual expression of target protein, albeit the toxicity that the exogenous
protein is causing to the bacterial cell. Therefore, over production of a protein will harm the bacterial
system and be targeted for degradation. pET vectors (pET 30b(+) and pET DEST 42) never
successfully produced protein. This could be because no solubility factors were present and the gene
was not codon optimized for bacterial expression. Due to these limitations, Gam1 was codon optimized
for bacterial expression, and cloned into an alternative vector system that will also assist in the folding
of the protein. The pCold Trigger Factor (TF) was selected to express Gam1. TF itself is a prokaryotic
ribosome associated cold shock chaperone of 48kDa that helps in protein folding under low temperature.
TF facilitates correct protein folding thus enabling efficient soluble protein production. In addition, at
lower temperature, basal expression of endogenous bacterial proteins is reduced, resulting in
overexpression of recombinant Gam1 in the total protein. Usage of expression tags, even as small as
His-tags, however, does have some drawbacks to have possibilities to interfere with the conformation
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and biological functions of proteins [89, 90]. For these reasons, Gam1 was cloned into pCold1 without
the usage of TF. However, when induction trials were completed (Fig. 1.13), recombinant Gam1 was
only detected in the insoluble fraction. Lower temperatures have been shown to destabilize hydrophobic
interactions [91]. Gam1 contains a hydrophobic region at the C-terminus, which is purported to be the
location where EloB/C (components of the ubiquitination pathway) binds [24]. Without a
chaperone[92] to protect that hydrophobic region, Gam1 could potentially aggregate, which may
attribute to mis-folded pCold1-Gam1 that will go to the inclusion bodies. This demonstrates that cold
temperatures alone did not solve the problem of producing soluble protein; TF is playing a major role to
protect the hydrophobic region in the proper folding of monomeric Gam1, especially at low temperature.
Removal of TF by protease digestion was unsuccessful, further supporting that TF and Gam1 interact
closely burying the linker region between them.

1.4.5.3 PURIFICATION AND IN VITRO SUMOYLATION
Purification of pET49b+-GST-Gam1 never reached homogeneity, even after a series of
chromatographic techniques and optimization trials; contaminants could not be removed (Fig 1.14-17).
As abovementioned, cooling to 16°C before induction is crucial for increased production of monomeric
Gam1 (Fig. 1.23), suggesting that the cold temperature facilitated protein folding and increased the
production of soluble TF-Gam1, and facilitated protein purification. Optimization of TF-Gam1
purification using affinity chromatography initially produced highly homogenous protein with a purity
exceeding 90%, however it was determined that using high concentrations of imidazole resulted in large
protein aggregates [93], which lead to the reduction of imidazole to obtain monomeric Gam1. Also, as
mentioned above cold temperature purification carried out at 4°C coupled with buffers pH’ed for these
temperatures greatly improved the production of monomeric Gam1, likely slowing the activity of
protease activity and slowed the course of protein degradation [94]. Previously, Gam1 has been
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demonstrated to inhibit global SUMOylation [11]; here, we want to verify that recombinant TF-Gam1
maintains its biological function. Experiments here showed that when incubated with recombinant TFGam1, NS1 SUMOylation was abridged (lanes 5- 10 of Fig. 1.28), when compared to the positive and
negative controls (lanes 1 and 3, Fig. 1.28). These results are consistent with previous results
demonstrating Gam1’s function to reduce SUMOylation [9]. However, SUMOylation was not
completely eliminated by TF-Gam1. Based on quantified data (Fig 1.29), it was estimated that
approximately 40% reduction of NS1 SUMOylation by TF-Gam1 compared to the controls. As
mentioned in the previous discussion, TF plays a vital role in the folding of Gam1, probably protecting
the C-terminus hydrophobic region and potentially hiding the contact region that binds to the E1
heterodimer. This might reduce recombinant Gam1’s SUMOylation inhibition efficiency as previously
demonstrated in vivo [24]. Moreover, the conformational heterogeneity [95] caused by the additional TF
could be another reason Gam1 cannot freely interact with E1 and completely abolish SUMOylation. To
a lesser extent, during the SEC purification of monomeric Gam1, dimeric form cannot be completely
separated (Fig. 1.23). Furthermore, it was observed that after SEC, storage of monomeric TF-Gam1 at
4°C for a prolong period of time gradually led to aggregation. This problem became more severe when
sample are more concentrated. This suggests that small percentage of dimer and aggregates could also
account for the reduction of Gam1’s activity.

1.5

SUMMARY AND FUTURE DIRECTIONS
Gam1 is the first viral protein found to globally inhibit cellular SUMOylation by directly

interfering with SUMO E1 activity. However, the structure of Gam1 is not available and detailed data
regarding the interface between Gam1 and the first enzyme in SUMOylation remain unclear. Thus,
recombinant Gam1 was cloned and expressed in various bacterial expression systems to obtain pure and
soluble Gam1 protein for further in vitro functional and structural studies. Most expression systems
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produced insoluble Gam1. The most soluble protein was produced from a system with the fusion tag of
Trigger Factor (TF), a cold temperature ribosome associated bacterial chaperone. TF-Gam1 was
expressed under low temperature and purified to high homogeneity through sequential chromatography
techniques. The purified protein was characterized by dynamic light scattering and by its ability to
inhibit in vitro SUMOylation reaction of target substrates. Recombinant Gam1 maintained it’s
biological function to a certain extent, TF dramatically helped the expression and purification of Gam1,
it might interfere with the function. Nevertheless, the current TF-Gam1 constructs are still useful for in
vitro functional and structural studies. Therefore, pure TF-Gam1 will be pre-screened for crystallization
trials. If a crystal is obtained, structure determination will be carried out and given that TF’s structure
has been determined [51], molecular replacement [96] can be utilized for structural calculations. Future
experiments will target co-expression of Gam1 with its native cellular counterparts to stabilize the
hydrophobic interface. Another future endeavor will include cloning into a vector with novel solubility
enhancers that can be removed during purification, or that do not affect biological activity. As a last
resort, if protein quality is not suitable for structure determination eukaryotic expression such as insect
baculovirus [97] cells will be utilized. The result from each of the cloning and expression vectors
selected is summarized in table 1.2.
These results will also establish a foundation for the future structural determination of Gam1 with or
without the binding components to investigate the interactions between Gam1 and its cellular target
proteins, which will deepen our understanding of how Gam1 impinges on the SUMOylation pathway as
well as its roles within viral replication.
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TABLE 1.2

SUMMARY OF GAM1 VECTOR OUTCOME

Vector System

Cloned

Expressed

Result

pET-30b(+)

Yes

Questionable

Expression Level too
Construct has mutation

pET-49b(+)

Yes

Yes

Degradation, low purity

N-p-DEST42-Gam1

Yes

No

Mutation

C-p-DEST42-Gam1

Yes

No

Mutation, Expression not
detected

N-pCold-TF

Yes

Yes

Degradation

C-pCold-TF

Yes

Yes

Testing functionality

pCold1-Gam1

Yes

Yes

Insoluble
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A

B

Fig 1.2 Agarose gel(s) of Gam1 PCR products for pET cloning. A) PCR
products from pET-DEST42 cloning, NG is the N-terminal His tagged
Gam1 and CG is C-terminal His tagged Gam1. B) PCR for pET49b(+).
The bands above PCR products were removed by purifying via gel
harvest. The molecular weight markers (MW) are in the first lane
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Fig 1.3 Agarose gel of Gam1 TOPO cloning screening. C stands for clone, and the wells above the
panel denote the clone selected for screening. The molecular marker is in the first well and labeled to
the left of the panel.

Fig 1.4 SDS-PAGE of small scale expression trials. pET49b+-GST-Gam1 supernatants with and
without IPTG induction. Molecular weight (MW) markers are in the first lane of each SDS-PAGE
with the corresponding size labeled on the left. Arrows on the right of each panel point to the
expected size of recombinant Gam1.
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Fig 1.5 Agarose gel of pCold-TF-Gam1 dual restriction enzyme digestion.
C stands for clone. The molecular marker is in the second well and labeled
to the left of the panel.

Fig 1.6 Selectivity plate of transformed Gam1 into bacterial competent cells.
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Fig 1.7 SDS-PAGE of pET30b+-Gam1. The lanes are labeled above the panel. The molecular
weight marker is in the first lane and labeled to the left of the panel.

Fig 1.8 SDS-PAGE of Gam1 affinity pulldown/ trial expression. The image on the bottom right
shows Empty BL21 (DE3) induced, as compared to pET-30b+-Gam1 on the left. The major
expression could be non-specific. Molecular markers are in the first lane and labeled to the left of the
panel.

40

Fig 1.9 SDS-PAGE of small scale expression trials. pCold-His-TF-Gam1 pellet (P) and supernatant
(S) samples with and without IPTG induction. Molecular weight (MW) markers are in the first lane
of each SDS-PAGE with the corresponding size labeled on the left. Arrows on the right of each panel
point to the expected size of recombinant Gam1.

Fig 1.10 SDS-PAGE of IPTG induction optimization. pCold-His-TF-Gam1 was induced with the
indicated concentrations of IPTG. Molecular weight (MW) marker is in the first lane and labeled to
the left of the panel.
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Fig 1.11 SDS-PAGE of pCold-His-TF-Gam1 concentrated after several chromatographic purification
techniques. The molecular weight marker (MW) is in the first lane and labeled to the left of the
panel.

Fig 1.12 SDS-PAGE of small scale expression trials. pCold-TF-Gam1-His pellet (P) and supernatant
(S) samples with and without IPTG induction. The molecular weight marker (MW) is in the first lane
and labeled to the left of the panel
.
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Fig. 1.13 SDS-PAGE of small scale expression trials. pCold1-Gam1 supernatant and pellet samples.
Molecular weight (MW) markers are in the first lane of each SDS-PAGE with the corresponding size
labeled on the left. Arrows on the right of each panel point to the expected size of recombinant
Gam1.
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Fig 1.14 SDS-PAGE of pET49b+-GST-Gam1 samples from GST affinity column: crude (CR), flow
through (FT), and elution fractions (A6-A10). Molecular weight (MW) markers are in the first lane of
each SDS-PAGE with the corresponding size labeled on the left. Arrows on the right of each panel
point to the expected size of recombinant Gam1.

Fig 1.15 SDS-PAGE of pET49b+-GST-Gam1 samples from GST affinity column with reduced flowrate (0.1 mL/min): crude (CR), flow through (FT), and elution fractions (A7, A8). Molecular weight
(MW) markers are in the first lane of each SDS-PAGE with the corresponding size labeled on the
left. Arrows on the right of each panel point to the expected size of recombinant Gam1.

44

Fig 1.16 SDS-PAGE of pET49b+-GST-Gam1 using HiTrap SP FF Cation exchange
chromatography. FT and LFT stands for Flowthough and late flowthrough, respectively. B5, B11,
and C7 are elutions. Molecular weight (MW) markers are in the first lane of each SDS-PAGE with
the corresponding size labeled on the left.

Fig 1.17 SDS-PAGE of pET49b+-GST-Gam1 using size exclusion chromatography. B3, B9, and C1
are elution fractions from the column. Molecular weight (MW) markers are in the first lane of each
SDS-PAGE with the corresponding size labeled on the left.

45

Figure 1.18 SDS-PAGE of pET30b+-Gam1 Ammonium sulfate precipitation trials. Different
concentrations of saturated ammonium sulfate (as indicated above the lanes) were used to remove
contaminants from the target Gam1 protein. The P stands for final pellet obtained. The molecular
weight marker is in the first lane and labeled to the left of the panel.

Fig. 1.19 SDS-PAGE of TF-Gam1 purification. Gravity flow affinity chromatography of TFGam1 using gradient concentrations (40 mM to 200 mM) of imidazole to determine the
optimized wash and elution conditions, FT stands for flow through. Molecular weight marker
is in the first lane and labeled to the left of the panel.
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Fig 1.20 SDS-PAGE and chromatograms of TF-Gam1 purification. TF-Gam1 affinity
chromatography using GE HisTrap HP with optimized wash and elution conditions determined in
(A) and labeled on the chromatogram.
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Fig 1.21 SDS-PAGE of TF-Gam1 purification. TF-Gam1 affinity chromatography using GE HisTrap
HP with 170 and 400 mM wash and elution conditions for increased purity. FT stands for flowthrough. The molecular weight marker is in the first lane and labeled to the left of the panel.

Fig 1.22 Size exclusion chromatography (SEC) purification of TF-Gam1. The three lanes
correspond to the three states of TF-Gam1. The molecular weight marker is in the first lane and
labeled to the left of the panel.
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Fig 1.23 Size exclusion chromatography (SEC) purification of TF-Gam1. Left and right panel
showing chromatograms before and after optimized purification conditions, respectively. Three peaks
of aggregation (AG), dimeric (DM) and monomeric (MO) forms of TF-Gam1 are depicted by arrows.
Lanes of an SDS-PAGE of TF-Gam1 are shown with arrows pointing to target peaks.
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Fig 1.24 SDS-PAGE of Ion exchange chromatography (IEX) purification of TF-Gam1 after
(SEC). Lane from an SDS-PAGE of TF-Gam1 with an arrow pointing to target peak.
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Fig. 1.25 The hydrodynamic size profile of TF-Gam1 characterized by dynamic light scattering
(DLS). (A), (B), and (C) represent the aggregated, dimeric, and monomeric forms of TF-Gam1
eluted from SEC, respectively. DLS profiles can be used to determine TF-Gam1 forms.
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Fig. 1.26 The Zeta potential surface charge measurement demonstrating TF-Gam1’s overall negative
charge.

Fig 1.27 The hydrodynamic size profile of High salt TF-Gam1 characterized by dynamic light
scattering (DLS). Polydispersity shifts to a higher hydrodynamic size with the addition of 500 mM
NaCl.
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Fig 1.28 In vitro SUMOylation of TF-Gam1. NS1 (substrate) was incubated in the in vitro
SUMOylation reaction mix comprising purified GST-SAE2/SAE1, GST-UBC9 in an ATPcontaining buffer with increasing amounts of TF-Gam1 for 1.5 hr at 37°C. Reactions were stopped
as described in Materials and Methods, loaded on SDS-PAGE, and scanned using
autoradiography. Arrows on left point to the expected size of SUMOylated/Un-SUMOylated
substrate. Samples are labeled below each lane in panel. For each protein sample tested,
“low” (1.2 µg) and “high” (2.4 µg) quantities of purified Gam1 were used in the reaction to
determine whether any dose dependent SUMOylation-inhibitory effects could be observed.
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Fig 1.29 The in vitro SUMOylation efficiency was quantified by densiometric scans of (A) for the
total amount of SUMO modified substrate using the un-SUMOylated substrate as internal
standard. Three replicates were performed to estimate the standard errors. Statistics t-test was
applied and p values were calculated and label accordingly above the bar graphs. * signifies statistical
significance using conventionally accepted p <0.05 criteria. Samples are labeled below each
corresponding bar in panel.
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CHAPTER 2:
STRUCTURAL INVESTIGATION OF THE ANTHRAX TOXIN RECEPTOR COMPLEXES

2.1

INTRODUCTION
In 2001, the importance of Anthrax was brought to light in the worst case of bioterrorism in the

United States. Letters containing spore-contaminated correspondence were sent to political figures and
media outlets, which resulted in a terrified nation as well as 22 infected with 5 deaths [98]. As a result,
one billion dollars were spent for decontamination; new legislations were passed and research to find
treatments thrived. The Anthrax disease is caused by the virulent strain of bacterium Bacillus anthracis:
a gram-positive, endospore forming, rod-shaped bacterium [99]. Anthrax infection is typical in
livestock namely: horses, sheep, cattle, and goats. The occurrence of Anthrax in humans is incidental
when they come into contact with those afflicted animals, which accounts for more than 95 percent of
Anthrax cases [100]. Intoxication with Anthrax can occur in three manners: Inhalation of the spore,
through a cut in the skin, or intestinal [101]. The virulent properties of Anthrax were not discernable
until the year 1954, when the toxin was discovered by Harry Smith in 1954 [99]. Anthrax toxin is a selfassembled complex, which is made up of three components: Protective Antigen (PA), Edema Factor
(EF), and Lethal Factor (LF). Individually these components are non-toxic. They only become toxic
once they form a complex after interacting with its respective cellular receptor [102]. Anthrax is
classified as an A/B toxin, meaning it needs two components (a delivery vesicle PA, and the payload EF,
and LF) [103-105]. PA and EF form Edema Toxin (ET), which cause non-lethal edema; PA and LF
form Lethal Toxin (LT), which is lethal to the cell [101]. Protective Antigen is the delivery vehicle for
EF and LF, and serves as the protein that recognizes one of the two known host cell-surface receptors:
Anthrax toxin receptor 1 (ANTXR1) or Anthrax toxin receptor 2 (ANTXR2) [105, 106]. Only after PA
(83 kDa) binds the receptor is it proteolytically processed by a cellular enzyme called Furin, leaving a
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truncated PA monomer of about 63 kDa in size. The truncated PA begins the formation of a heptameric
complex (pre-pore), which then attracts free (1 to 3) EF and LF proteins. The entire complex then
undertakes endocytosis, where the pre-pore becomes a pore under low pH environment within the
endosome after acidification and effectively releasing EF and LF into the cytoplasm [104, 107]. The
mechanism is visualized in Fig 2.1.

2.1.1

PA AND ATXR2
PA contains four domains, of which domains 2 and 4 have been implicated in receptor

binding[108]. Domain 2 is involved in heptamer formation and is found along the inside of the
heptamer. Domain 4 interacts with the receptors binding domain and has been suggested to play a role
in the pH dependent pore formation [108, 109]. Despite the high sequence homology between ATXR1
and 2, binding activities with PA are quite different [110]. Mutagenesis studies performed by Heather
Scobie, et. al in 2006 demonstrated the physiological importance of ANTXR2 in the disease
progression, showing that a mutated form of PA could still interact and cause a lethal infection, while
ANTXR1 played a smaller role [110]. ANTXR2, the one of primary interest to this research has four
components. It is characterized as a type I transmembrane protein, with the primary interaction with PA
relegated to the von Willebrand Factor A domain (VWA) [111]. It has what has been called a stalk
region connected to a transmembrane domain, and finally a cytosolic domain. It is well known that the
VWA domain is crucial for Anthrax toxin infectivity, but recently the stalk region has been implicated
as an immunoglobulin-like (Ig) domain; which has demonstrated the importance of disulfide bonds for
infection [112, 113]. In this research, structural studies utilizing Cryo and Negative Stain Electron
Microscopy were performed on the Protective Antigen in complex with ANTXR2. It is expected that
there will be a vast difference in the Ig domain with the WT and a Mutant version where disulfides have
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been mutated, making this the first characterization of WT PA and a Mutant in which the disulfide
linkage has been altered.

2.1.2

ELECTRON MICROSCOPY
Cryo Electron Microscopy (Cryo-EM) of biological specimens namely for single particle

reconstructions utilizes samples that have been prepared and frozen in an aqueous environment to mimic
their native state. In the past decade, electron microscopy of biological samples has come to the
forefront of structural biology. There exist many obstacles that need to be resolved when handling
biological samples in Cryo-EM such as: limited dosage of electrons due to potential radiation damage,
the need for high vacuum, and the resulting low contrast due to the fact that higher dosage of electrons
will damage the sample under investigation [114]. One of the steps taken to minimize these issues is
vitrification of the sample, which means to freeze the sample in a very rapid manner as to produce ice
that will not impede with data collection [115]. Another step is the advent of cryo-protecting the sample
by introducing cold stages and as well as maintaining the sample at cryogenic (cryo) temperatures while
collecting data; which allows for slightly higher dosage of electrons, while reducing radiation damage
incurred [114]. A collection of individual macromolecules can be observed using the above-mentioned
techniques, which is now approaching atomic resolution [116-118]. Once data have been collected,
individual micrographs will be processed. This process is ubiquitous regardless of the software utilized.
In this case, EMAN, and FREALIGN were used for the image processing and reconstructions. The
reconstruction procedure begins by either digitizing the films, such as scanning the micrographs with a
Nikon coolscan 9000, or transferring data from the CCD to a portable hard-drive. The image processing
will commence by isolating single particles from the hundreds of other particles and background within
the micrograph. Once all the particles have been “boxed”, they undergo a series of pre-processing steps
including: image normalization, defocus level determination, and correction of the contrast transfer
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function (an artifact that is a byproduct of the microscope). Utilizing the pre-processed images from the
previous steps, an initial model was generated for the following reconstruction cycles [116]. Within the
iterative process, there are two major tasks to be conducted: orientation determination and threedimensional reconstruction. In the orientation determination, using the initial model or the reconstructed
model from the previous cycle, the individual particles’ information regarding orientation and center is
calculated. After this refinement cycles with the entire dataset is performed where the angles and
orientation information will be used to reconstruct a new model for the ensuing cycles. This iteration
cycle will be continued until the highest possible resolution from the dataset is obtained. In this chapter,
we will compare the reconstruction between the wild type complex and a mutant in an effort to
understand how the efficient pore formation has been disrupted by removal of the disulfide bonds in
pore formation. The results obtained will guide the development of novel treatments for Anthrax
infection.
2.1.3

SUMMARY

Overall, the key aspect covered in this introduction pertains to the reason for the boom in
Anthrax investigation, namely the mechanism by which the toxins work and are shuttled into the cell.
Inhalation of Anthrax spores poses a serious threat, and developing novel treatments that can halt the
illness are crucial. Progression of the disease has mainly focused on the first domain of the human
receptor (ANTXR 2), however, recent evidence points to a major role undertaken by the second Ig-like
domain in the delivery of the toxin. As a result, structural studies utilizing transmission electron
microscopy were performed. Cryo-electron microscopy is now at the forefront of macromolecular
reconstruction, with many advances made in data collection, which helps to preserve biological samples
in their native environment, while getting closer to atomic resolution. Data processing for single particle
reconstructions is divided into three phases: preprocessing the images, building the initial model, and an
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iterative refinement cycle to obtain the best resolution reconstruction from the data. In the remainder of
this chapter, we will discuss how the reconstructions of Anthrax toxin complexes were carried out and
comparing the structural differences in the Mutant (second domain disulfide mutation) with the WT in
effort to locate the position of the second domain of the ANTXR 2 in the complexes.

Fig 2.1 Model of Anthrax toxin receptor. Adapted from [101]

2.2

LONG TERM GOALS AND SPECIFIC AIMS
As mentioned in the introduction, multiple biochemical data as well as structural data have been

collected for the PA and domain one (VWA) of ANTXR 2. However, not until recently has domain two
been implicated in the overall course of infection. The long-term goal of this research is to determine
high-resolution structures of PA and VWA and Ig-like domains of the ANTXR 2 receptor in complex.
Information obtained would lay the foundation in understanding the role domain two of the receptor
plays in toxin delivery. In this dissertation, a total of six Negative stain as well as Cryo-EM datasets of
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the above mentioned mutant and WT were processed and final models were generated. One specific
aim is proposed, which will test the hypothesis that the complex structure of PA with domains one and
two of ANTXR2 will maintain different conformations with respect to WT and the domain 2 (Ig-like)
Mutant.
Specific Aim: To generate a three-dimensional (3-D) model of the WT and MUT datasets and
highlight the key structural differences in ANTXR 2 Ig-like domain. Cryo-electron Microscopy as well
as negative stain datasets of the abovementioned complexes was collected and three-dimensional models
were generated to investigate the structural details pertinent to Ig-like doamin of the ANTRX 2 receptor.
Results obtained from these experiments will show that coupled with the biochemical analyses (Pedro
Jacquez/Dr. Sun) Ig-like domain organizations within the macromolecular assembly plays a critical role
in the efficient delivery of the toxins into the cell. Previous research has focused on the interaction of
PA with VWA of the ANTRX 2 receptor; here we are interested in observing the conformation of the
Ig-like domain and how the mutation of the disulfide bonds abrogates the function of toxin delivery.
2.3

MATERIALS AND METHODS

2.3.1

EM SPECIMEN PREPARATION AND DATA COLLECTION
The PA/receptor complexes were negatively stained on ultrathin carbon film (Ted Pella #01824)

using 2% sodium phospho-tungstate. Negative stain data were collected on JEOL 3200FS transmission
electron microscope equipped with field emission gun and in-column omega filter (University of Texas
at El Paso). 3.5 uL sample aliquots of purified protein complexes were blotted onto plasma cleaned thin
holey carbon grid (C-flat CF-1.2/1.3-2C) and manually plunged into ethane at liquid nitrogen
temperatures. Cryo-EM data were recorded on a Gatan 4k X 4k CCD using a JEOL 2200FS
transmission electron microscope equipped with field emission gun and in-column omega filter
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(University of Texas Medical Branch) operating at 200 kV nominal magnification of 60,000x. The
sampling rate was at 15 micron/pixel, generating a pixel size of 1.97 A at the sample.

2.3.2

IMAGE PROCESSING, 3D RECONSTRUCTION, AND DOCKING OF ATOMIC MODELS

Single particle reconstructions depend on high-end microscopes to collect the data, coupled with
multicore computers for high throughput calculations. Multiple platforms to process the data exist,
which may use different but very similar approaches. Many of the features from individual programs
have over-lapping functionality, and many times certain aspects of the software can be combined from
multiple programs to carry out the desired calculation. The major differences observed are relegated to
the manner in which classification, CTF correction, and model refinement are performed.

2.3.2.1 PARTICLE SELECTION AND PREPROCESSING
Image analyses and three-dimensional reconstructions were carried out using the EMAN and
FREALIGN [119] imaging suites. Particles were manually selected using EMAN1 software suite [120].
Data were linearized and normalized using EMAN2.1 [121]. Before image selection, the micrographs
will be normalized with proc2d and the command edgenorm, which adjusts the means and standard
deviation of the images. In order to accommodate the individual particles, a box size ~ 1.5-2 times the
size of the longest particle dimension (160) was selected [122]. Only particles selected (BOXER) from
micrographs demonstrating no visible signs of drift and minimal astigmatism were used in the
reconstruction. Images demonstrating sample that is mono-disperse were targeted, and those
demonstrating too high a sample concentration were avoided. This program displays two windows
when in use; one for the entire micrograph, and another boxed multiple times that is updated once a
selection (particle) has been made on the micrograph. EM datasets were boxed multiple times, to
include more particles and remove aggregated particles. Individual micrographs were visually inspected
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to ensure the CTF was concentric; all images not displaying this quality were not utilized in further
processing. To save out the boxed particles, save boxed particles (IMAGIC format .img) for further
EMAN processing and save box DB (Coordinate file) for re-boxing purposes were both selected. The
defocus of each micrograph was determined by CTFit, verified and applied by e2ctf.py. Proc2d was
utilized to append all the particles from each respective dataset (Cryo-EM) and generate a start file. The
start file was then used to generate reference-free 2-D class averages from the particles in the dataset;
refine2d.py or e2refine2d.py (negative stain) was run using 8-10 iterative cycles and a number of classes
to contain approximately 30-40 images representing a class. The program will compare the similarity of
a particle to others in the stack, and then place into an appropriate class based on cross-common line
schemes. Particles were centered using the Cenalignint command or within the e2refine2d.py command.
Bad class averages were manually removed and the good classes extracted for usage in the refinement
steps. Phase flipping was applied during the reconstruction to correct for the contrast transfer function
(CTF).

2.3.2.2 INITIAL MODELS AND RECONSTRUCTION
The reference-free initial model was generated using EMAN2.1 e2initialmodel.py, using the
processed stack from the previous steps. Multiple initial models were utilized for the refinement
procedure. Maps were calculated from the dataset itself, or the available crystal structure with ANTRX
2 VWA domain (filtered to a resolution of 20 Å). The maps were iteratively refined using EMAN2.1
using the processed stack coupled with the respective initial model using a 90% classification selection
and 30-70% of the classes to be used in generating the next model. In this step, once again particles can
be eliminated from the reconstruction process, allowing only a percentage of the class averages to be
included in the model generation. In each cycle of refinement, the particle center and the orientation
information of the projected image were cross-correlated with projections (Fig 2.3) of the current 3D
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model and subsequently utilized for the next round of refinement. The process was repeated over various
cycles in an effort to improve the structural features that could be distinguished. The final 3D
reconstruction for each dataset was computed from a number of particles listed in table 2.1. Fourier
shell correlation analysis was used to assess the quality and convergence of the refinement cycles. The
resolution of each map (Table 2.1) was determined Fourier shell correlation (FSC) at a cutoff of 0.5
(EMAN2.1). Cryo-EM maps were docked with the X-ray crystal structure of PA complexed with
Anthrax Toxin Human Receptor VWA (PDB 1TZN), using UCSF Chimera [123]. All illustrations of
structures were rendered using UCSF Chimera.

2.3.2.3 DOCKING OF ATOMIC STRUCTURE INTO ELECTRON DENSITY MAPS

The docking of the atomic models was either performed by visual inspection and or utilizing the
“Fit in map” function from Chimera under the menu of Tool/Volume/Data, which has the capability to
fit the atomic coordinates into a density map, or one map into another for comparison [124].
2.3.2.4 TABLES AND FIGURES
TABLE 2.1
Dataset

Pixel
Size
(A/pix)
1.97

DATASET SPECIFICS OF RECONSTRUCTIONS.

Magnification Defocus
range

Micrograp
hs taken

Micrographs Total
used
Particles

Cryo-EM
TF_WT
Cryo-EM 1.97
TF_MUT

74627

0.8-3.5

465

206

52186

Total
Particles
used
29490

76074

0.87-2.236

272

83

32808

15134

Cryo-EM
WT
Negative
Stain NS
TF_WT
NS_
TF_MUT
NS_WT

1.97

74627

1.026-3.38

345

90

28484

10104

1.02

146785

0.3-1.45

31

30

10582

7995

1.02

146785

0.72-1.59

76

71

16947

10972

1.02

146785

0.42-1.48

91

76

16901

11932
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Fig 2.2 Schematic diagram of the EMAN reconstruction process.
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Fig 2.3 Projections from EMAN2.1 generated during iterative reconstruction.

Fig 2.4 Raw image of an EM micrograph depicting disperse particles. A 200 A scale bar is in the
bottom right corner.
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Fig. 2.5 Particles that have been separated from the micrograph into individual “boxes”.

Fig 2.6 2-D CTF power spectrum of a micrograph, and the fit line to correct the CTF.
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Fig 2.7 Classes demonstrating broken particles, octomers and hexamers when performing 2-D
classification.

Fig 2.8 Negative Stain class averages demonstrating top, side and tilt views.
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Fig 2.9 Initial models from cryo-EM reconstructions (EMAN1). Top and side views from left to
right.

Fig 2.10 Initial models from Negative stain EM reconstructions (EMAN2.1). Top and side views
from left to right.
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Fig 2.11 Cryo-EM reconstructions of Anthrax toxin receptor complexes using EMAN2.1, from top to
bottom TF-WT, TF-MUT, and WT.
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Fig 2.12 Side view projections from reconstructed map to be used as a reference for particle
selection.

Fig 2.14 Crystal structure of VWA domain of the Anthrax toxin receptor with homology modeled Iglike domain. Secondary elements have been colored as red (helix), green (beta-strand), and blue
(coil). Disulfide bonds denoted at C279-C255 and C230-C315.
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Fig 2.14 NS-WT reconstruction superimposed on the PA-VWA receptor complex. The second
modeled domain (Ig-like) was located at the base of the structure.
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Fig 2.15 Negative stain reconstructions of TF-MUT (Green) and TF-WT (Orange) superimposed on
the available PA-VWA receptor complex crystal structure.

Fig 2.16 Negative stain reconstructions of TF-WT (Orange) and TF-MUT (Green) superimposed on
the available PA-VWA receptor complex crystal structure. TF-WT clearly has more density where
the VWA domain of the receptor is located as compared to the disulfide TF-MUT.
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Fig 2.17 Negative stain reconstructions of TF-WT (orange mesh) superimposed on the WT (light
blue). The density correspondent to the location of VWA domain of the receptor match well, as
compared to the TF-MUT.

2.4

RESULTS AND DISCUSSION

2.4.1

DATA PROCESSING
All data processing steps were performed on three multicore workstations (Xi Computer Corp.).

Initially BOXER from EMAN1 was utilized to individually select out particles (Fig 2.4-2.5) from
micrographs into boxes of 160 X 160 square pixels, with a pixel size of 1.97 Å. Images demonstrating
too much aggregation and/or ice contamination were eliminated from further calculations. Particles
were normalized and CTF defocus (Fig 2.6) calculations utilizing CTFit were performed. Manual
screening of micrographs’ CTF were analyzed to ensure it was concentric and not astigmatic. This
assessment would typically eliminate more than 30 percent of the original data collection. The resulting
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corrected particles were appended into a single stack file “start.hed” for further processing. Results
from Cryo-EM datasets encountered many problems in the initial particle selection stages. It was
observed that the majority of densities boxed out were predominantly top views. It was very difficult to
distinguish side views from damaged particles or other artifacts. Heterogeneity of the sample could be
observed when generating 2-D class averages, demonstrating octomers and hexamers and broken
particles (Fig 2.7). Bad classifications were removed and the new stack was utilized to center and align
the images (Cenalignint). Reclassification was once again repeated. The same processes were carried
out with Negative stain samples, however the EMAN2 software suite was utilized. Particle orientations
were more uniform, albeit, viable particles were significantly reduced.

2.4.2

INITIAL MODEL BUILDING AND ITERATIVE REFINEMENT

The 10-20 best representations of top, side, and tilt views were utilized to generate an initial
model (Fig 2.8). Initial models using EMAN1 software would always generate an elongated cylindrical
model that would be refined with the dataset (Fig 2.9), and then used to execute iterative refinement
cycles with the entire datasets. The exact premise for model generation was utilized for the datasets
utilizing EMAN2.1, however initial models were much closer in shape (Fig 2.10) to the PA/ANTXR 2
crystal structure. Collectively, reconstructed models in the cryo-EM datasets had an elongated side (Fig
2.11) view, suggesting lack of side views represented in the actual density map. Side view projections
(Fig 2.12) were generated as a visual guide to conduct re-boxing, building a new initial model and
refinement. This only marginally improved the quality of the data, and the density maps all appeared
featureless when viewing from the side views (Fig 2.11). Multiple model refinement cycles were
computed, and three-dimensional density maps with resolutions at 13.3, 11, and 13.1 (FSC criterion of
0.5) for the TF-WT, TF-MUT, and WT respectively. All reconstructed models fit the available crystal
structure of PA with VWA of the ANTXR 2 receptor. Key differences from the reconstructions of WT
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and TF-MUT were observed at the interface between domain 4 of PA and VWA relative to the actual
conformation at the base of the complex (Fig 2.11). The WT reconstructions (TF-WT and WT) were
longer when compared to the TF-MUT along the side view. Furthermore, the localization of VWA at
the base of the PA, representing ANTXR 2 VWA maintains an inward type curvature towards the inside
of complex for the TF-MUT. In the WT reconstructions, this density was extended outward and the
contour of the density was more prominent as compared to the TF-MUT (Fig 2.11).
The negative stain (NS) reconstruction was able to locate the Ig-like domain in the PA/ANTXR2
complex from the NS-WT reconstruction, and from the NS-TF-MUT it was possible to see
conformational differences in the VWA domain of the ANTXR 2 receptor. In silico analyses of domain
2 or the Ig-like domain of the ANTXR 2 receptor have been reported to form an Ig fold [112, 125],
however the position within the complex and structure remain unknown. Multiple iterative refinements
were calculated and a low resolution ~14 Å NS-WT was generated (Fig 2.13). The Ig-like domain of
ANTXR 2 was also homology modeled (I-TASSER, Fig 2.14) and subsequently fit into the density map
(Fig 2.13). The modeled domain fit the density at the base of the NS-WT complex, which is just
beneath the first domain of the ANTXR 2. An important observation pertinent to the density is that it is
relatively weak when taking the molecular weight into account. The density only appeared after the
standard deviation was one deviation above the average, whereas the remainder of the map fit the
available crystal structure quite well at three and a half deviations above the normal. This could suggest
that the Ig-like domain is very flexible in solution as opposed to the PA and the VWA domain of
ANTXR 2. To that end, the structural model did demonstrate a connecting hinge region between
domains one and two of the receptor, which would allow for flexibility between the domains.
Biochemical analyses performed previously (Dr. Sun) have demonstrated no effect on PA pore
formation with the addition of the TF tag, and in terms of data collection appeared to improve the
stability, contrast, and orientation of the particles within the grid. This however, did not assist in
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locating the Ig-like domain in the reconstructed maps, as it appeared that both the TF and Ig-like domain
flexibility made it difficult to map those regions. There is a long linker region between the TF tag and
Ig-like domain, which could account for the flexibility. Density maps are shown at a contour level three
and a half standard deviations above the average, in order to remove the unstructured densities below
VWA of the ANTXR 2.

2.4.2.1 DOCKING OF ATOMIC STRUCTURE INTO ELECTRON DENSITY MAPS

The overall shape of all cryo and negative stained reconstruction maps matched that of the PAVWA-D1 heptamer crystal structure (PDB 1TZN). After manually translocating the PDB coordinates
into the map roughly by visual inspection, the Chimera “fit in map” tool can dock the structure with
numeric calculations with a much higher accuracy. Particularly, the PA structure docks into all the maps
very well, indicating no major conformational changes occurred in that area. The differences observed
do appear between ANTXR2 VWA and Ig-like domains.
Given that all the reconstruction contain the heptameric PA part, in the discussion below, the
complexes will be named according to the different ANTXR2 components. For instance, the
reconstruction of TF-WT means the reconstruction of heptameric PA complexed with wild type
ANTXR2 and a TF tag at the N-terminus of the receptor. Only negatively stained WT reconstruction
shows partial density of ANTXR2 Ig-like domain (Fig 2.13), indicating the hinge region between the
VWA domain and Ig-like domain are very flexible. This hinge region also is where the N-terminus of
VWA domain located due to a disulfide bond linking the N- and C-termini of the VWA domain.
Therefore, when the TF tag is linked to the same hinge region, the TF will interfere with the already
flexible Ig-like domain, preventing it from being visible in all TF-tagged reconstructions that used
symmetry averaging. Ig-like domain structure was homology modeled and docked into the partial
density observed in the WT reconstruction. No literature has previously reported the position of the Iglike domain and this is the first time that the Ig-like domain’s relative location to the VWA domain is
determined.
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Comparison between negatively stained TF-WT and TF-MUT reconstructions show that the TFMUT reconstruction has much less density where the VWA domain is located. The difference can
potentially be attributed to the double disulfide mutations in the Ig-like domain, thus affecting the VWA
domain’s folding, leading to a more flexible and/or partially unstructured VWA domain. In order to
assess whether the structural differences observed between TF-WT and TF-MUT were not attributable
to the TF tag, negatively stained TF-WT reconstruction was superimposed on that of WT (Fig 2.17). No
obvious differences in the densities correspondent to the VWA domain of ANTXR 2 were observed.
This further demonstrates that the TF tag plays no role in affecting the conformations of PA and VWA
domain of ANTXR2.
2.4.3

DISCUSSION
The cryo-EM datasets did not generate models with useful structural information. The reasons

for the poor data quality are as follows. One caveat of EM reconstructions is the potential for sample
heterogeneity. One of the major expectations when collecting cryo-EM data is that the macromolecules
are “identical” in structure. Meaning sample heterogeneity [126-128] is not observed, as was the case in
our reconstruction. All densities pertaining to a plausible particle were selected, and when 2-D class
averaging was performed, we found hexameric and octameric complexes as well as broken particles.
All of these factors could have contributed to the lack of structural details from the cryo-EM datasets. It
also becomes challenging to produce a monodisperse specimen for cryo-EM data collection, relegating
you to add components that could drastically reduce image contrast. To this end, cryo-EM intrinsically
has poor contrast, which can make it difficult to discern a good particle from a denatured or broken
particle. If most of the particles are not representative of the intact target structure, then you can expect
the final model to be representative of that poor data. From our data collection utilizing cryo-EM, it was
observed that many of the particles were mixed quite ubiquitously with these unwanted particles. To
solve these issues, the complexed macromolecular assembly needs to be freshly purified and
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immediately used for data collection. This alone will not completely remove the sample heterogeneity,
however programs in the data processing packages will be utilized to remove those particles from the
reconstruction. Another major issue with single particle reconstructions is the possibility that the
macromolecular complex maintains a preferred orientation [129, 130] on the grid. As the name implies,
this happens when the molecule absorbs on the carbon grid in one or a few orientations. This was one of
the issues seen in our cryo-EM datasets, in which the top “flower” shape was predominant. Therefore,
our cryo-EM data was unable to reach higher resolutions was the lack of side views, which could
account for the elongation observed in the models. Modifying the method of data collection by tilting
the specimen can solve this; however, that introduces new problems of electrical charges on the vitreous
ice thus leading to image drift [131]. Another solution could be to utilize detergents or vesicles to
disrupt the orientations with the grid. To obtain a high-resolution reconstruction, implementation of
these solutions will be carried out and new data will be collected.
The negative stain reconstructed models showed more structural features, namely the visibility of
the Ig-like domain in NS-WT. This might be attributed to the higher contrast inherent to negative stain
EM technique. The negative stain datasets also contained more side views as compared to the cryo-EM
datasets, perhaps due to two possible reasons. One is the fact that it was easier to locate side views due
to the high contrast of negative stain. Secondly, the supporting carbon film might orient more complexes
towards side views. As a result, not only the Ig-like domain of the ANTXR 2 receptor was visible, the
negative stain reconstructions denote key structural differences in the VWA domains of NS-TF-WT and
NS-TF-MUT related to the disulfide bond mutation in domain two of ANTXR 2. The fact that toxin
translocation is inhibited as shown in biochemical data (Jacquez, P. et. al.) [113], it is plausible that the
C255-C279 disulfide bond within the Ig fold maintains a pivotal role in the stabilization of the Ig
domain. When this critical interaction is abridged, conformational or even unfolding events may occur
in the Ig-like domain. Consequently, this structural change could potentially alter the functioning of the
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PA. Moreover, based on negative stain reconstruction of PA with GroEL [132] and lipid nanodiscs
[133], there is a 50-60 Å gap that is between the membrane and the cap of the PA. The height of our
modeled receptor VWA plus Ig-like domains (NS-WT) is 60 Å. It could be the case that the receptor
ANTXR2 is still associated with the complex after pore formation, surrounding the pore to stabilize the
PA. Previous studies have shown a critical loop near residue F427 in domain 4 of PA involved in both
pore formation and translocation [134, 135]. Docking of crystal structures into negative stain EM
reconstructions allowed the positioning of VWA domain at the bottom of the PA pore cap within reach
of F427 flexible loop. Previous electron paramagnetic measurements of a spin probe attached to Cys in
PA (F427C) suggested rearrangement of the residue towards the 7-fold axis in pre-pore to pore
formation [135]. This could likely implicate the VWA domain influences the function of PA pore
through the interaction with residues positioned outside the F427 loop. Therefore, if the double
disulfide mutant alters the conformation of the VWA domain, efficient delivery of the toxin may be
impinged. In summary, the negative stain reconstructions were able to provide models with more
structural features, which may provide key insights to the potential mechanism that the Ig-like domain
plays in the delivery of the toxin into the host.

2.4.4

SUMMARY AND FUTURE DIRECTIONS
Bio terroristic acts in 2001 brought Anthrax research to the forefront of scientific research

looking for novel treatments and potential cures from the infection. In this research, the main objective
was to determine the role of the Ig-like domain of ANTXR 2 in the progression towards toxin release
into the afflicted cellular host. Previous research has focused mainly on the VWA domain of the human
receptor (ANTXR 2); however, recent evidence suggests that the second domain (Ig-like) plays a pivotal
role in the delivery of the toxin. As a result, structural studies utilizing transmission electron
microscopy were performed. Results obtained from negative stain electron microscopy located the
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position of the Ig-like domain and demonstrated conformational differences in the VWA domain of the
receptor complexes between the wild type and mutant. Cryo-EM datasets presented multiple issues,
therefore, future work will aim to fix the orientation issues and obtain more side views using alternatives
discussed above. In addition, recent EM studies of the PA pore structure were reconstructed bound to
GroEL [132], yielding more side views of the pore formation. Future cryo-EM data could utilize GroEL
to perhaps reduce the preferred orientation and yield more side views. Also, given the added density,
the contrast of the particles will be improved and make it a little easier for particle selection.
Furthermore, the PA pore has also been placed into nanodiscs and lipid vesicles [133, 136, 137], which
could also be targeted in our reconstruction efforts as well. It is unclear as to the exact molecular details
about how the Ig-like domain interferes with PA pore formation, whether by direct or indirect contact
with the PA pore. Therefore, obtaining higher resolution models with more structural features will be
imperative in deciphering the mechanism by which the Ig-like domain disulfide bond modulates PA
pore function. Understanding the molecular details of the toxin delivery mechanism will aid in the
development of novel therapeutics and potential treatments against the lethal Anthrax disease.

80

CHAPTER 3:
STRUCTURAL INVESTIGATIONS OF CORE CIRCADIAN REGULATORY COMPONENTS

3.1

INTRODUCTION
Approximately 50 to 70 million Americans suffer from sleeping disorders, which debilitate

overall health and longevity [138]. Some of the risk factors include hypertension, diabetes, obesity,
depression, heart attack, and stroke [138]. Much of these maladies are attributed to disruption of the
circadian rhythm. Circadian rhythm is an intrinsic, roughly 24 hour timing mechanism whereupon
oscillations of biochemical, physiological, and behavioral processes are synchronized with
environmental elements such as light, nutrients, and temperature [139]. In mammals, this master
biological “clock” is embedded in the hypothalamus that has control over clocks in peripheral tissues
[140]. Circadian rhythm is found in most living organisms ranging from cyanobacteria to humans, and is
a vital component for organisms to adjust their metabolism so as to use energy efficiently [139]. One
example of circadian disruption in humans would be demonstrated by traversing various time zones after
a long distance flight, resulting in what is known as “jet lag”. Thus, resetting the “clock” or reducing the
disruption period can provide benefits for patients with sleep disorders and for persons in high-stress
occupations such as medical staff, long distance drivers, pilots and soldiers who need to maintain
alertness under prolonged dangerous situations. For instance, accidents can be reduced if the circadian
disruption can be modulated to decrease fatigue [141]. The strategy in developing new therapeutics
requires a deeper understanding of the mechanisms in modulating the circadian rhythm, which has been
investigated for over two decades, albeit the precise molecular mechanism by which the central
components are regulated has yet to be determined. This can be partially attributed to the lack of
structural information of core circadian regulatory molecules. In this proposal, structural biochemical
techniques such as X-ray crystallography combined with traditional biochemical and biophysical
81

methods will be applied to investigate one core regulatory component, Cryptochrome (CRY), in the
mammalian circadian clockwork. Cryptochromes are a set of blue-light sensitive flavoproteins, which
have been found in plants, bacteria and animals [142-144]. Information obtained will challenge
hypotheses about CRY and its usage of FAD as a cofactor, and will benefit the development of new
therapeutic agents targeting circadian-related diseases [142-144].

3.2

BACKGROUND AND SIGNIFICANCE

Circadian related genes have been investigated since 1984, with the first observed genes
discovered in drosophila mutants, then later in mammals [142-144]. It was found that the circadian
rhythm was driven by a transcription-translational loop within the cell (Fig. 3.1). It has been shown
[145] that two transcriptional factors CLOCK (Circadian Locomotor Output Cycle Kaput) and BMAL1
(brain and muscle aryl hydrocarbon receptor nuclear translocator like-1) form a heterodimer and bind a
DNA transcriptional element known as E-box found in the promoter region of many circadian genes,
including CRYs [143, 146-148]. The transcriptional activation complex serves as positive elements in
establishing the circadian rhythm, and can be manipulated by most clock modifiers. For instance, once
CRY accumulates in the cytoplasm (reaches a certain threshold), it will down-regulate its own
production by inhibiting the transcriptional activity of the aforementioned activation complex. This will
generate an inherent time-delayed negative feedback loop, controlling the rhythmic expression of
various clock-controlled genes[149] (Fig. 3.1).

82

Fig 3.1 A schematic diagram of the transcriptional/translational negative feedback loop governing
the circadian rhythm.
Cryptochromes are a class of photoreceptors maintaining the ability to modify the circadian
rhythm in almost every species [150]. CRY’s are multifunctional proteins, which have been determined
to play viable roles in signal transduction important for growth, development, and
magnetosensitivity[151-153]. Interestingly, CRYs are homologous to photolyases (PLs), both of which
are classified in the same family of flavoprotein photoreceptors that mediate responses to ultraviolet and
blue light exposure. Despite maintaining structurally conserved homology between species, CRYs and
PLs maintain distinct functions[154]. PLs utilize visible light to repair DNA that has incurred ultraviolet
light damage. CRYs on the other hand, act as blue-light photoreceptors in circadian systems [155]. To
date, it is known that CRYs coupled with PLs preserve common structural motifs, the use of Flavins and
intrinsic photoactivation mechanisms[156, 157]. It is possible to further separate animal CRYs into two
distinct subclasses, which are based on phylogeny and dependence upon light. The CRY’s that pertain
to the type I subfamily pose as photoreceptors, and magnetoreceptors; whereas type II CRY’s
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(mammals) are non-light dependent and play major roles in repressing the negative feedback loop at the
level of transcription. [158]
The differences that have been scrutinized between members of the CRY family types I and II
are relegated to the substrates in which are employed and the manner in which activation mechanisms
are brought forth. It remains a mystery how animal CRYs synchronize the circadian rhythm and
whether this regulation requires any ligands. In 2011, the full-length atomic structure of drosophila
CRY (dCRY) was determined using X-ray crystallography. It is the first animal CRY whose structure
has been determined. This structure is composed of multiple alpha helices with many loops and
approximately 13 beta sheet structures. dCRY also includes two domains: the amino-terminal
photolyase homology domain (PHD), and an FAD binding domain conserved from photolyase. The
structure has an additional C-terminal tail (Fig. 2), which has been proven to be a nuisance in obtaining
the structure of mammalian CRYs.

Fig 3.2 dCRY and PL demonstrating variable C-terminal CTT found in CRY’s. Adapted from
Zoltowski, 2011
Given the lack of structural information pertaining to mammalian circadian core components,
scientists have based their assumptions utilizing the dCRY model to predict ligand recognition and
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attempt to decipher the manner in which they interaction with other clock-controlled genes such as
CLOCK and BMAL1. Zoltowski, et al observed that the composition of dCRYs C-terminal tail (type I)
and that of PLs is conserved and serine rich, whereas type II CRYs have three Cysteine residues that are
postulated to bind close to the active site of type II CRYs [155]. This could suggest a different purpose
for the active site, which would shed light on human CRYs function. The variable C-terminal tail of
dCRY was shown in Fig 3.2 to emulate the DNA binding position observed in PLs. Even though
sequence homology is not preserved and DNA repair mechanisms are not undertaken by CRYs. The Cterminal region does however pose a physiologically important effector role in CRYs[159], namely
could play a key role in the interaction with nucleic acids, flavin cofactors such as FAD. In 2013, Xing,
et al compared the crystal structures of mammalian CRY2 in its free form, FAD bound, and in complex
with ubiquitin ligases; suggesting regulation via ubiquitin degradation pathway [160]. Furthermore, it
was observed that FAD binding to mCRY2 was exposed rather than buried within the binding pocket
such as drosophila (6-4) PL (Fig 3.3). This could explain why expression models of human CRYs have
shown to exhibit low levels of flavin binding [161-163] which could suggest the potential usage of the
catalytic core for other functions as opposed to enzymatic functions such as DNA repair as seen in PLs.

Fig. 3.3 Density map representation of mCRY2 compared to drosophila photolyase showing the
comformation of the FAD binding pocket. Adapted from Xing, 2013
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3.2.1

SIGNIFICANCE

Determining the crystal structure of the mammalian CRY will deepen our knowledge about the
functions of CRYs. Much of what is known about the function of mammalian CRYs has been based on
structures of related CRY models such as dCRY. However, the different mechanism used by type I
CRYs (drosophila) to synchronize the circadian rhythm is light dependent and targets the protein
“timeless” (TIM) for it subsequent degradation. Type II CRYs (mammals) conversely interact more
directly with the heterodimer complex to inhibit its function, thus playing a more direct role in
regulating the circadian rhythm [142-144]. Comparative protein sequence homology shows that dCRY
and human Cry1 (hCRY1) only maintain approximately 40% overall homology, which could further
indicate a distinctive function of hCRY1’s variable C-terminal tail from that of dCRY. From the
structure, it may be possible to predict the mechanism by which the protein functions and the manners in
which it influences interacting components. By determining the full-length structure of hCRY1, it will
be plausible to predict the manner in which it regulates the circadian rhythm and mechanisms by which
it affects the transcriptional activation complex. This would shed light on the function of the catalytic
core and the usage of the C-terminal tail not found in PL members.
3.2.2

LONG TERM GOALS AND SPECIFIC AIMS
As mentioned above, the full-length structure of mammalian CRY’s have not been obtained.

Moreover, the function of the Photolyase homology region (PHR) of hCRY1 is still unknown. The
long-term goal of this research is to obtain a full-length atomic resolution structure that can provide
molecular insights as to what these regions perform in the feedback cycle. Within this dissertation,
recombinant hCRY1 has been cloned, expressed, and purification from bacterial expression system is
being optimized. Protein obtained from optimized purification will be utilized for future structural
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determination of Gam1 with or without the binding components. Two specific aims have been proposed
in this research to test the main hypothesis unlike dCRY (type I), hCRY1 (type II) utilize their Photolyase
homology domain (PHD) catalytic core for DNA binding.
In this research, two specific aims are proposed to test the hypothesis and examine the function
of hCRY1.
Specific Aim One: To optimize purification hCRY1. The objective will be to obtain large
quantities of pure protein for crystallization and for conducting biochemical and biophysical studies.
Specific Aim Two: To characterize the ligands binding to hCRY1. The pure protein obtained in
specific aim one will be used to examine the binding of potential cofactors by various biochemical and
biophysical methods.
The experimental aspects were designed in this matter so they could support or refute the
hypothesis. Function can in part be explained with the structure, which requires a highly homogenous
protein for crystallization carried out in Specific Aim One. Once the protein is crystallized and the
atomic structure is determined, it will be possible to identify the two known structural domains. These
domains display different functions as demonstrated in the structure from type I CRYs (dCRY),
therefore the structure of hCRY1 can support or refute the stated hypothesis in part from the atomic
structure if DNA is indeed found to be a ligand. Additionally, it will demonstrate any other type(s) of
ligands they bind, and whether or not they serve common purposes from homologous structures. Also,
the biochemical and biophysical experiments will corroborate the results from structural studies in terms
of specific ligands namely DNA and their capacity to bind hCRY1.
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3.3

MATERIALS AND METHODS

3.3.1

CLONING
The full-length gene sequence was: amplified via PCR, restriction endonuclease digested, and

ligated into an expression vector(s) see table 3.1. During the PCR primer design, expression tags were
added to either the N-terminal or C-terminus of hCRY1 gene. These tags are for affinity purification,
enhancing solubility, and assisted folding. Following cloning, expression trials were carried out to
optimize protein expression. See section 1.3.1 for detailed methods regarding directional cloning and
into pCold-TF. hCRY1 was also obtained in a FLAG-tag (p3XFLAG-CMV-14) containing construct
(Courtesy Dr. Erquan Zhang, Beijing School of Sciences) and also cloned into pMal-p4X with E. coli.
maltose binding protein (MBP) at the N-terminus. The FLAG tag is a short 8 amino acid residue
peptide utilized to purify via an Anti-FLAG antibody column. It has been utilized in a variety of
expression systems from mammalian, yeast [164] and bacteria [165], and more importantly has been
shown to not interfere with native protein function [162, 166]. Maltose binding protein has been used as
a solubility enhancer when fused to proteins that are otherwise difficult to express [167-169]. Inducible
expression with the tac promoter generates a fusion of MBP-hCRY1. Cloning was performed according
to specification in table 3.1. E. coli strains as mentioned in section 1.3.1 were utilized, with the added
strain BL21 Codon + (Agilent technologies). This strain similar to Rosetta2 (DE3)pLysS contain extra
rare codons that are not as frequently utilized in bacterial expression [170].

3.3.1.1 EXPRESS TARGET PROTEIN:
Section 1.3.2 describes overlapping methods for hCRY1 expression, for more information
reference to that section. For maltose binding protein construct culture was grown at 37°C agitating at
220 rpm until an OD600 of 0.5 is reached. Then the culture was immediately induced with 0.3 mM IPTG
and incubated an additional three hours at 37°C agitating at 200 rpm. Culture was processed as
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mentioned in section 1.3.2. For FLAG-tagged hCRY1, expression was carried out as mentioned in
section 1.3.2.1.

3.3.2.2 COLD INDUCTION PROTEIN EXPRESSION

hCRY1 protein was produced in pCold-TF with a C and N-terminal His tag as detailed in section
1.3.2.2, however cultures were grown to an OD600 of 0.8, at which point they were removed from the
incubator and maintained at room termperature induced with 0.1 or 1 mM IPTG for 30 minutes.
Afterward, Culture was placed back into the incubator at 16°C for 12 hours with 200 rpm agitation.
Cultures were harvested following the aforementioned section.

3.3.3

PROTEIN PURIFICATION TRIALS

3.3.3.1 WESTERN BLOT
10% acrylamide SDS-PAGE gels were transferred to polyvinylidene difluoride (PVDF)
membranes utilizing the Bio-Rad Mini-PROTEAN 3 system and transfer buffer (25 mM Tris, 192 mM
Glycine, and 20% methanol). Membranes were blocked overnight at 4°C with 5% nonfat dry milk
reconstituted in TBST (50 mM Tris pH 7.4, 150 mM NaCl, 0.02% NaN3, and 0.1% Tween-20). The
next morning membrane was washed 3X with TBST and incubated with Anti-FLAG HRP conjugate
(Courtesy of Dr. Sun; 1:1000) for 1 hour. Following incubation, membrane was washed as described
above and processed with Immobilon Western Chemiluminescent HRP substrate (Millipore). After 5minute incubation, image was exposed for 3-5 minutes and images were captured on X-ray films
(Phenix Research Products).
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3.3.4

BIOCHEMICAL CHARACTERIZATION

3.3.4.1 DLS IN HCRY1 CHARACTERIZATION

DLS of hCRY1 were collected following specifications mentioned in section 1.3.4.1. Briefly,
dilute hCRY1 sample taken immediately following SEC fractionation was used for DLS measurement.
Sample concentration of 0.1 mg/mL was used in characterization. Sample was maintained within the
same buffer as mentioned in section 1.3.4.1.

3.4

RESULTS AND DISCUSSION

Efficient cloning via the amplification of the hCRY1 gene encoding ~1.9 kbp (Fig 3.4) was
performed using PCR and ligated into the vectors listed in Table 3.1. These constructs were further
verified by DNA sequencing. The resultant constructs were transformed into BL21 (DE3), BL21
Codon+, and Rosetta 2 (DE3) pLysS E. coli (Fig 3.5). In some cases, dual restriction enzyme digestion
was used to verify the insertion of the hCRY1 gene into various vectors (two shown in Fig 3.6-7). After
induction trials, constructs with vectors pET-DEST42 (with or without N-terminal 3X-FLAG) and
pMal-p4X (MBP-3XFLAG-hCRY1) produced either very little or highly degrading protein (Fig 3.8 A),
even after pooling multiple batches of protein crude together for purification purposes. The protein was
suspected to be unstable and degrade when expressed on its own, which is why the MBP vector was
selected, as it is known to help solubilize challenging proteins[171]. His-affinity beads pull-down
assays were used to access the expression of pET-DEST42 C-terminal 6X His construct, in which no
band correspondent to hCRY1 at the expected size was detected (Fig 3.9). The major protein obtained
by the pull-down assay was one that has molecular weight of slightly higher than 25 kDa. Since the His
tag was on the C-terminal, this suggests an N-terminal degraded product of hCRY1. Western blot
analyses were utilized to assess the expression of pET-DEST42-hCRY1-His with C-terminal 6X His and
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pMal-p4X (MBP-FLAG-hCRY1) constructs (Fig 3.8 and 3.13). Results demonstrated that soluble
protein was being obtained from these vectors. Nevertheless, expression quantities were quite limited
and the mixture of extraneous proteins exceeded that of our target. More importantly, degradation of
hCRY1 was observed (Fig 3.8 and 3.10). In addition, given that hCRY1 is a member of blue-light
receptors, dark expression (no light exposure) trials were carried out for pMal-p4X (MBP-FLAGhCRY1) and pET-DEST42-hCRY1-His constructs to see if this had an effect on hCRY1 production (Fig
3.10-11), but similar results were obtained as compared to the regular expression.
The hCRY1 is a eukaryotic gene with codon usages different to prokaryotic. The lack of viable
hCRY1 produced in the aforementioned constructs led to having hCRY1 codon optimized and de novo
synthesized (Genscript). In addition, the codon-optimized hCRY1 was cloned into pCold-TF (Fig. 3.12)
that has several advantages for obtaining protein (see discussions in Chapter 1 section 1.3.1.2). As
shown in (Fig 3.13), the crude sample of induced hCRY1 as compared to the non-induced sample
displays an additional band of the correct molecular weight corresponding to hCRY1. Expression of
hCRY1 in pCold-TF expressed a suitable amount of protein, which was then tested in small scale
affinity purification trials to assess the binding to the column (Fig 3.14). The wash and elution
conditions were optimized for large scale purification using HisTrap HP column (GE) as shown in (Fig
3.15, 3.17). Similar to pMal-p4X-MBP construct, light/dark expression tests of pCold-TF-hCRY1 did
not show difference (data not shown). Affinity purified hCRY1 was then utilized for size exclusion
chromatography (SEC) (Fig 3.16, 3.18). The hCRY1 protein was eluted in the void volume of the SEC
suggesting that it was a large aggregate. Dynamic light scattering further confirmed that the only peak
obtained (hCRY1) was indeed much larger than its monomeric or even dimeric state (Fig 3.19).
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As mentioned in section 1.4.2, protein expression from bacterial expression systems encounters
multiple problems. By far, mammalian cryptochromes were almost exclusively expressed in eukaryotic
cell systems [160, 162, 172, 173], some of which only cloned a truncated portion of the entire gene
[174-176]. To date, only two mammalian cryptochrome (mouse CRY1 and CRY2) structures have been
determined [160, 175], both of which are truncated. This is likely attributable to the fact that the Cterminal region, which is highly flexible, exposed [177] and unstructured [178, 179] causes problems
when attempting to produce a crystal. More importantly, the C-terminus has been found to easily
degrade [160] as also seen in our results (Fig 3.8, and 3.14-16), making it quite difficult to obtain fulllength hCRY1. Also, it was recently shown that mouse CRY1 (mCRY1) becomes phosphorylated at the
C-terminus, which regulates the length of circadian period and serves to stabilize CRY1’s activity [180].
Therefore, re-cloning hCRY1 into a vector with a C-terminal His tag was carried out, anticipating that
only full-length protein would be purified because those truncated or degraded hCRY1 will not have the
His tag to interact with affinity resin. Unfortunately, the C-terminal His-tag construct did not resolve the
degradation issue, as demonstrated in Fig 3.15-16. Even after further purified by SEC, the aggregated
form of hCRY1 still contains degradation (Fig 3.18). Nevertheless, the only elution profile observed
from the C-terminal His construct corresponded to aggregates, similar to previous constructs.

3.5

SUMMARY AND FUTURE DIRECTIONS

Bacterial expression systems were first targeted due to their relative ease and scalability,
therefore, hCRY1 will be re-cloned with only the PHR and a short extension after that, following the
methods performed by Nangle et al for mCRY1 [175]. Given the current aggregated status of bacterial
expressed recombinant full length hCRY1, denaturing and refolding in the presence of it’s binding
partner hPER1 could potentially yield a stable protein complex useful in structural studies. Along the
same line, dual protein expression vector will be used in which hCRY1 and hPER1 will be co-expressed
in hopes that they stabilize each other. Alternatively, it might be useful to stabilize hCRY1 with small
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molecular compounds, which have been found to lengthen the circadian period by preventing mCRY1
degradation [175]. Given that hCRY1 is a eukaryotic gene, and solubility or folding issues cannot be
overcome in prokaryotic systems, eukaryotic expression systems such as yeast, or the insect baculovirus
system may be used [97]. The drawback of multiple steps for generation of recombinant clones; low
protein yield, and high cost for media are reasons why the eukaryotic expression systems were not tried
in the first place. Once highly homogenous hCRY1 is produced, crystallization trials will be performed.
Members of the PL/CRY family have previously been crystallized [155, 172, 175, 181, 182]; therefore,
conditions similar to those successful crystallizations can be screened. Subsequent to obtaining optimal
crystallization conditions and suitable size crystals are produced, endeavors to determine the atomic
structure will follow standard X-ray crystallography procedures [183, 184]. The resultant atomic
structures will facilitate to generate a plausible regulatory mechanism how hCRY1 acts upon the
transcriptional activation complex. Structural comparative analyses among hCRY1, dCRY, and E. coli
Photolyases (PLs) will shed light on C-terminal tail regulatory function as well as the difference
between PLs and CRYs. Moreover, structural analyses of the contact interface between hCRY1 and its
potential binding components including ligands will reveal critical residues that are pertinent in the
circadian rhythm. Information learned from these critical residues will be further compared with other
CRY models and PLs to determine whether they are conserved between species, which will further
prove or disprove the hypothesis that type 1 and 2 CRYs have different regulatory functions [156-158].
Having the atomic structure will aid our understanding of the mechanism with which CRY imparts to
modulate the circadian rhythm. In addition, the available structures will show whether the catalytic core
of hCRY1 binds FAD similar to the PL/CRYs in homologous species or binds other circadian
components/DNA. The high resolution structures obtained from the research will deepen our
understanding of the catalytic function of hCRY1 and its overall role in modulating the circadian
rhythm.
Generating an atomic structure of hCRY1 will facilitate the long-term goal of conducting
functional studies in terms of the entire transcriptional activation complex. Information obtained from
the structure can help build new hypotheses pertinent to binding capabilities to the heterodimer complex,
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which could be tested in future mutagenesis experiments at critical contact residues. The proteins of the
heterodimer transcriptional activation complex CLOCK/BMAL1 can be purified and crystallized
individually then assembled in the presence of hCRY1 and/or hPER1 and examined utilizing cryoelectron microscopy (cryo-EM). The individual atomic structures can then be fitted into the electron
density map generated from cryo-EM to produce a pseudo-atomic structure of the complex. Overall,
this complex structure would provide insight into how the transcription/translational negative feedback
loop is regulated at the molecular level. Moreover, critical residues of the interfaces between these core
regulatory components in the mammalian circadian clockwork can be targets for therapeutic agents that
disrupt DNA binding or regulate the inhibitory function of hCRY1. The knowledge obtained will
facilitate the development of treatments against circadian related diseases.

3.6

TABLES AND FIGURES
TABLE 3.1

Clone
pET-DEST42hCRY1-His
(the PCR was
done in three
steps)

pET-DEST-423X-FLAGhCRY1
(the PCR was
done in two
steps)

hCRY1 gene amplification primers

Primer
Sense Primer Outside
5' GCTAGGATCCAAGGAGATATTCACCATGGGGGTGAACGCCGT
BamHI
Sense Primer Inside
5' CACCATGGGGGTGAACGCCGTG
For TOPO cloning
Antisense Primer
5'GGCACTCGAGCGTCCTTCAATATTAGTGCTCTGTCTCTGGACTTT
XhoI
Sense Primer Outside
5'GCTAGAGCTCAAGGAGATATTCACCATGGGGGTGAACGCCGTGCA
XhoI
Sense Primer Inside
5' CACCATGGGGGTGAACGCCGTG
For TOPO cloning
Antisense Primer
5'CCGCGGATCCTCTTCCTTCAATATTAGTGCTCTGTCTCTGGACTTT
BamHI
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pMal-p4XMBP3XFLAGhCRY1

pCold-TF-HishCRY1
Codon
Optimized

pCold-TFhCRY1-His

Sense Primer Outside
5' GCTAGAGCTCAAGGAGATATTCACCATGGGGGTGAACGCCGTGCA
SacI
Sense Primer Inside
5’ CACCATGGGGGTGAACGCCGTG
Antisense Primer
5’CCGCGGATCCTCTTCCTTCAATATTAGTGCTCTGTCTCTGGACTTT
BamHI
De novo synthesized construct (Genscript) in pUC57 digested with 5’-NdeI and
3’ HindIII

Sense Primer
5' GCGCTACATATGGGTGTGAATGCGGTCCACTGGTTCCG…
NdeI
…TAAAGGTCTGCGTCTGCACGACAAT
Antisense Primer
5’ GGTCGAATTCTTAATGATGATGATGATGATGGCGACC…
EcoRI
…TTCAATGTTCGTGCTCTGACGCTGGA

Fig 3.4 Agarose gel of hCRY1 PCR product. Molecular weight marker is in the
first well, and labeled on the left of the panel.
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Fig 3.5 Ampicillin plates containing transformed hCRY1 after ligation reaction. The plate
on the right denotes a negative control, while the plate on the left is the transformed
ligation.

A

B

Fig 3.6 A) Agarose gel of hCRY1 dual digested ligation product. The black arrow denotes
the location of hCRY1 at the correct size after the ligation and transformation reaction. B)
Agarose gel of ligation trial of hCRY1 with a shift in plasmid position in the second lane.
The adjacent lanes are uncut and cut plasmids as reference. The molecular weight marker is
in the first well and labeled to the left of the panel.
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Fig 3.7 Agarose gel of hCRY1 PCR screening following ligation. Wells labeled as in figure,
with the positive control in the second well and the molecular weight marker in the first well and
labeled to the left of the panel.

Fig 3.8 Western blot of hCRY1 FLAG-tag affinity pulldown in pET-DEST 42. The first and second
lane represent crude samples, and the fourth lane is the pulldown hCRY1. The middle lane(s) contain
the molecular weight marker, which is labeled to the left of the panel. As shown in the figure,
hCRY1 is degrading, which is more severe in the SDS-PAGE gel (data not shown).
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Fig 3.9 SDS-PAGE of hCRY1-pET-DEST42 affinity pulldown assays. Step elutions were
performed at the indicated concentration of imidazole labeled above the lanes. FT stands for flowthrough. The molecular weight marker is in the first lane and labeled to the left of the panel.

Fig 3.10 Western blot analysis of hCRY1-MBP affinity pulldown assay. The first lane is crude
sample. The third lane is the pulldown product.
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Fig 3.11 SDS-PAGE of hCRY1 dark expression pulldown assays. hCRY1 was applied to affinity
column washed with binding buffer and eluted with 100 mM imidazole, to test binding of protein.
FT stands for flow-through. The molecular weight marker is in the first lane and labeled to the left of
the panel.

Fig 3.12 Agarose gel of hCRY1 after ligation into pCold-TF and dual restriction enzyme digested.
wells two and four are uncut vector of clones 3 and 7 respectively. Wells three and five are dual
digested hCRY1. The molecular weight marker is in the first well and labeled on the left of the
panel.
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Fig 3.13 SDS-PAGE of hCRY1 induction trials. Lanes two and three are non-induced
supernatants of small and large scale induction respectively. Lanes three and five are pellets of
of small and large scale induction respectively. The sixth lane is induced hCRY1 at the correct
fusion size as denoted by the black arrow to the right of the panel. The molecular weight marker
is in the first lane and labeled to the left of the panel.

Fig 3.14 SDS-PAGE of hCRY1 small-scale affinity purification trials. Lanes are labeled above the
figure, and the black arrow to the right of the panel denotes hCRY1-TF fusion size. The molecular
weight marker is in the first lane and labeled to the left of the panel.
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A

B

Fig 3.15 A) SDS-PAGE of hCRY1 affinity purification on HisTrap HP. Lanes are labeled above the
figure with indicated imidazole concentrations. B) SDS-PAGE of hCRY1 (0.5L) on HisTrap HP
using a higher gradient to wash out contaminants and purify hCRY1-TF fusion to higher
homogeneity. FT stands for flow-through. The molecular weight markers are in the first lane(s) and
labeled to the left of the panel.

Fig 3.16 SDS-PAGE of hCRY1 (silver stained) after size-exclusion chromatography purification.
The second lane contains the only elution fraction obtained from the column. The molecular weight
marker is in the first lane and labeled to the left of the panel.
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Fig 3.17 HisTrap HP (GE) affinity chromatogram of TF-hCRY1. The first peak is the wash at 110
mM and the second is elution at 200 mM imidazole concentration.
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Fig 3.18 Size exclusion chromatogram of TF-hCRY1. The only peak observed corresponds to the
elution of hCRY1.
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Fig 3.19 Dynamic light scatter profile of TF-hCRY1 purified via affinity and size exclusion
chromatographies.
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CHAPTER 4:
BIOCHEMICAL INVESTIGATION OF AN ANTIBODY AGAINST CANCER

4.1

INTRODUCTION
In 2013 alone, over 1.6 million new cases of cancer were reported, with an expected mortality of

over half a million [185]. The importance of cancer in everyday life is clear, which necessitates the
development of novel detection and treatment methods. Carbohydrates are vital macromolecules found
within living organisms that play critical roles within the cell. Currently there are a handful of glycanderived drugs on the market that have proven efficient in the treatment of the Flu, anticoagulation, and
red blood cell production [186-189]. In addition many cell surface proteins are glycosylated and their
glycan moiety serve as targets for microbes and viruses, cell adhesion and development, impact cancer
spread, and regulate countless receptor:ligand interactions [187]. In the past, carbohydrates were
believed to be poorly immunogenic or of little value as antigens for vaccine development [190].
However, this has changed after the discovery of cancer specific glycan immunogens [191, 192]. Even
though the study of glycans as an immunogen is in its infancy with a little over 15 years, it is now clear
that carbohydrate and glycoconjugates can serve as highly immunogenic B-cell epitopes (recognized by
the immune system by antibodies) [191]. This discovery has vastly increased the efforts of
glycobiologist to explore the glyco surface molecules as targets for cancer, used as therapeutics,
vaccines, and biomarkers.
Antibodies are ubiquitously produced throughout vertebrates, and divided into five different
classes (IgA, IgD, IgE, IgG, and IgM). Each class also has subclasses such as IgG1, IgG2, etc [193].
Antibodies work as “sticky” proteins as defensive molecules that recognize and attaches to its specific
antigen (foreign substance). Once attached, they can recruit components of the immune system to
eliminate the antigen [194, 195]. The most common Immunoglobulins (Ig), are IgG, which are found in
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all body fluids and accounts for approximately 80% of all antibodies within the body [196]. IgG
demonstrates a Y-shaped structure (Fig 4.1) with two identical arms representing Fab fragments
(antigenic contact) connected to Fc through a flexible linker [197]. Antibodies are made up of two light
chains linked by disulfides with two heavy chains; where the heavy chain (H) is a 50 kDa subunit and
the light chain (L) is 23 kDa [198]. Each antibody has two copies of distinct antigen-binding site,
located at the tip of the Y-shaped antibody. The antigen-binding site is comprised from variable
domains of one light chain (VL) and one heavy chain (VH) [198]. The interaction between an antibody
and its antigen directs the immune response and is indispensable for the development of novel vaccines
for diseases [199].

Fig. 4.1 Classic IgG Antibody structure depicting the different regions of the antibody. Adapted from
[200].
Despite remarkable advances made in the field of glycobiology, progress has stalled due to the
unknown mechanism by which a carbohydrate (antigen termed immunogen) is presented to elicit a
response. As denoted by Gerstenbruch, S. et. al., over 2000 antibody-carbohydrate interactions have
been investigated and over half have shown cross-reactivity with other glycans [201]. The low affinity
and molecular flexibility have deterred the usage of structural studies to examine these interactions. The
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abovementioned cross-reactivity coupled with the lack of structural information has stagnated the
successful development of carbohydrates as vaccine to target cancer. The interactions between protein
and carbohydrates are still poorly understood. Due to the relatively weak interactions between proteins
and monosaccharide, proteins require oligosaccharides for binding. The most well-characterized
carbohydrate binding protein is lectin, a big family of surface proteins found throughout many species
that serve a wide range of functions. One of the chief functions carried out by lectins involve the contact
between two cells [202]. As for antibodies against carbohydrates, very few structures are available [191,
192, 203] due to the poor immunogenicity of carbohydrate for the above stated reasons. This has
hindered the development of carbohydrates for cancer therapeutic or diagnostic agents. Therefore, it is
imperative to bridge this need for more antibody-glycan complex structures. More antibody/glycolantigen structures will contribute in general to unravel the interactions between protein and carbohydrate
at the atomic level, which will facilitate the design and development of more effective carbohydratebased immunogens.
16A, the antibody under investigation, is an IgG1a derived from mouse that targets the Tn
antigen O-linked N-acetylgalactosamine (GalNac) epitope of MUC1 from cancer cells [204].
Antibodies (including 16A) toward glyco-peptides with authentic glycosylated forms of MUC1 were
produced by Song, W. et. al. with 25 fold higher binding versus the non-glycosylated form. In specific,
16A antibody recognizes the glycopeptide sequences of RPAPGS(Tn)TAPPAHG and the Tn antigen is
linked via O-glycosylation to the Ser residue of the peptide sequence. In order to characterizing the
antibody-carbohydrate interactions, the biotinylated glycopeptides, RPAPGS(Ac3GalNAc)TAPPAHGdPEG™11-Biotin (Fig. 4.2), and non-glycosylated form RPAPGTAPPAHG-dPEG™11-Biotin, were
custom synthesized (Peptide International Inc., Louisville, KY). Subsequent deacetylation was
performed to produce RPAPGS(GalNAc)TAPPAHG-dPEG™11-Biotin [204]. The binding
characteristics between these glycopeptides and 16A were analyzed using ELISA and surface plasmon
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resonance [204]. ELISA of glycopeptides RPAPGS(Ac3GalNAc)TAPPAHG and
RPAPGS(GalNAc)TAPPAHG showed higher binding affinity (25 fold higher) as compared to the nonglycosylated RPAPGTAPPAHG peptide. However, surface plasmon resonance measurement of 16A
demonstrated similar binding to both glycosylated and non-glycosylated forms. Nevertheless, 16A will
provide us an interesting candidate to investigate the structural features that lead to a better
understanding of the interaction between 16A and the abovementioned glycopeptides at the atomic level.
In order to improve our understanding of how carbohydrate-antibody interacts, we must couple
structural biology to determine a wide range of parameters. These include: how carbohydrates of a
potential immunogen should be presented, the amount of carbohydrate epitopes present, their proximity
to one another, the relative size and complexity, the portion(s) of the carbohydrate involved in the
contact interface, and the role of the peptide backbone in terms of recognition.

Fig. 4.2 Structure of biotinylated glycopeptide (RPAPGS(Ac3GalNAc)TAPPAHG) that is recognized
by 16A antibody. Adapted from Song, W. et al. 2012
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4.2

MATERIALS AND METHODS
Initial batches of the 16A antibody were purified by Dr. Dapeng Zhou at MD Anderson Cancer

Center using the following protocol: mouse ascites were mixed 1:10 with binding buffer (1M Glycine
pH8.6, 300 mM NaCl). Samples were then loaded into ProSep-vAUltra- (cat # 115115824-Millipore),
subsequently washed with binding buffer and eluted with elution buffer (0.1M Citric Acid pH 3.0, 150
mM NaCl). Eluted antibodies were immediately neutralized with 1M Tris pH 9.0, and dialyzed in PBS
buffer (10 mM Na2HPO4, 1.8 mM KH2PO4, 140 mM NaCl, 2.7 mM KCl pH7.4).
4.2.1

CELL CULTURE
Hybridoma cells (provided by Dr. Dapeng Zhou at MD Anderson Cancer Center) were grown at

37°C with 5% CO2 in T-flasks. 16A was maintained in Hybridoma-SFM media (Gibco Cat# 12045)
with 10% fetal calf serum and Penicillin-Streptomycin (Gibco Cat# 15140) at a final concentration of
100 ug/ml streptomycin, and 100 units/ml penicillin. Cell counts were performed daily to ensure cells
were healthy and maintained between 2x105-1x106 viable cells/ml, and split accordingly. Cultures were
slowly adapted to the above media without fetal calf serum. Cell culture was then used for large-scale
production of 16A in spinner flasks (Bellco Glass, Inc).
4.2.2

PROTEIN A AND PROTEIN G PURIFICATION.
Protein A is from the bacterium Staphylococcus aureus and has very strong affinity to IgGs [205,

206]. Due to its high affinity for IgG’s Fc regions, Protein A has been utilized for purification of IgG’s
to high homogeneity [207, 208]. One issue is that Protein A has a weaker affinity towards mouse IgG1
[209]. Protein G, another protein from Streptococcal bacteria, also binds the Fc region of
immunoglobulins. Protein G, however, binds IgG much stronger than Protein A [210, 211].
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16A antibody was centrifuged at 5,500 xg for 10 minutes to remove cell debris and filtered by
0.45µm filter before loaded onto Hitrap HP Protein A column (GE), or onto Protein A resin (Goldbio)
suspended in a 1mL gravity column and equilibrated with 10 mL of binding buffer (50 mM Tris pH 8.0,
2.7 mM KCl, 137 mM NaCl). Gravity chromatography was used to optimize the binding and eluting
conditions. 50 mL of supernatant was run via gravity flow and any unbound sample was washed out
with the same buffer, while allowing only the Antibody remains bound to the column. The flow through
was collected in a separate sample tube for analysis. Elutions were tested using 1 M Glycine pH 2.8, or
0.1M Citric Acid pH 3.0, 150 mM NaCl. The optimal eluting conditions were found to be the 0.1M
Citric buffer. Chromatographic techniques were performed in the same manner for HiTrap HP A and
protein G (GE).
4.2.3

16A FAB FRAGMENTATION
Due to the flexible loop between Fab (variable region) and Fc (constant region), intact antibodies

do not readily pack into crystal arrays. Fragmentation of full-length antibodies needs to be performed to
obtain the Fab domains for crystallization. There are many proteases available for the generation of
various fragments of Fab; one of the enzymes commonly utilized is Papain. Papain is a cysteine
protease found in papaya (Carica papaya) [212]. Papain breaks the linkage of an antibody between the
Fc and Fab regions generating three fragments: two copies of Fab (~50 kDa) and one copy of Fc (~25
kDa) [213, 214]. Ficin, Another enzyme similar to papain, is a non-specific sulfhydryl protease coming
from the latex of the fig tree Ficus glabrata [215]. Fab obtained from ficin fragmentation has been
found to have an improved reactivity and yield as compared to that from papain, specifically for mouse
IgG1 [216, 217].
16A fragmentations were prepared by proteolytic digestion of the purified antibody with various
enzymes including: immobilized papain (Pierce cat # 20341), immobilized ficin (Pierce; cat # 44881),
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crystal papain (Sigma-Aldrich; cat # 76218), and mouse IgG1 Fab/F(ab’)2 preparation kits (Pierce Ficin
based; cat # 44980). Multiple trials were carried out to optimize the fragmentation of the antibody in
order to obtain Fab fragments. Purified intact antibodies were buffer exchanged into the proper
digestion buffer required for the specific enzyme. Small scale enzymatic digestion conditions were
tested by: (1) changing the enzyme(s) to antibody ratio; (2) increasing the concentration of antibody; (3)
increase or decreasing the total enzyme used; (4) changing digestion temperature; and (5) changing
reaction receptacles. Samples were taken out of the digestion at different time points and quenched with
the addition of SDS-PAGE buffer (reducing or non-reducing) and 20 mM iodoacetimide. SDS-PAGEs
were used to analyze fragmentation results.
4.3

RESULTS AND DISCUSSION
16A received from Dr. Zhou as well as obtained from Hybridoma cells were successfully

purified to homogeneity (Figures 4.3-6) using Protein A or Protein G chromatography, and the best yield
was from Protein G. Purified 16A antibody was then utilized for subsequent enzymatic digestions.
Small scale digestion trials following the conditions detailed with the kits or literature conditions were
carried out first. A predominant 37 kDa fragment was observed on non-reducing SDS-PAGEs from
three of the four digestion systems (Fig 4.7). Non-reducing SDS-PAGE gel of immobilized ficin kit
digestion showed the intact antibody without fragmentation (Fig. 4.8), suggesting the antibody is
resistant to ficin using the company suggested condition. The normal Fab fragment should be 50 kDa in
non-reducing SDS-PAGEs. The 37 kDa fragments appear to be over digested fragments of the intact
antibody. Approximately 50 enzyme digestions with various conditions (temperature, time, enzyme to
substrate ratio, concentration, etc.) were carried out in order to obtain Fab fragments with little success.
Results obtained in most cases were over digested with 37 kDa fragments (Fig. 4.9, 4.10, 4.11, 4.12,
4.13 with immobilized papain, immobilized ficin, crystal papain 1:200, crystal papain 1:80, and IgG1
mouse preparation kit 1:50; respectively). In relatively rare conditions, the antibody was resistant to the
digestion (Fig 4.14 immobilized papain). When significantly reducing the enzyme to substrate ratio E:S
(e.g. below 1:500), only partial digestion of the antibody was observed only yielding 37 kDa fragments.
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None of the conditions completed yielded fragments at the expected 50 kDa size, pertaining to Fab.
During the multiple trials, in order to have ample antibody samples for fragmentation, hybridoma 16A
cell culture was utilized to produce the antibodies in house. More than 3 L of serum free media (SFM)
with the 16A antibody were produced and purified to high homogeneity via protein G chromatography.
Protein A has less specificity for mouse IgG1a as mentioned above, therefore protein G was utilized as
the method to produce highly pure 16A. This yielded approximately 1.5-2 mg of antibody after this
purification technique from 500 mL of media. The sample produced locally and that provided by Dr.
Zhou showed the same over digestion fragments, suggesting the antibody source and purification
procedure is irrelevant to the digestion. Moreover, 16A was sent to the MD Anderson Cancer Center to
perform the Fab fragmentation with the same outcome.
4.4

SUMMARY AND FUTURE DIRECTIONS
As mentioned above, multiple efforts were made to optimize the enzyme and actual conditions to

perform the digestion reactions. While viable Fab fragments were not produced, the protocol for
producing, and purifying 16A to homogeneity is now established. Utilizing various protocols, suggested
from the kit as well as exploring the literature, those conditions that do not generate Fab have been
recognized. Suboptimum digestion conditions consistently produced an over digested antibody.
Literature has rare instances where this piece maintained function [218], however, upon further
characterization of 16A was shown not to be the Fab fragment. Therefore, future experiments will aim
to crystallize the intact antibody. This however, might prove challenging given the flexibility [219] of
the hinge region. Within the current protein database, only 4 full-length antibodies have been
crystallized. The hinge regions of 2 of them were modified to be rigid. Another alternative would be to
incubate 16A with the target glycopeptide to protect the Fab domain. It was shown in some cases that
the 37 kDa fragment is due to the digestion of the flexible epitope-bind loops at the top of Fab [220].
Co-incubation with the antigen could potentially make those loops more rigid and resistant to enzymatic
digestion [221]. Thirdly, the cDNA sequence encoding for 16A can be obtained and utilized to
construct bacterially expressed single chain antibodies [222, 223]. These alternatives might help to
obtain functional regions of 16A, open the gate towards the ultimate goal to determine its structure.
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After obtaining large quantity of 16A variable domain, pre-crystallization screening kit (PCT™ PreCrystallization Test, Hampton Research) will be used to determine the ideal antibody concentrations for
crystallization. Crystallization screening of 16A variable domain with or without its glycocojugates
will ensue to obtain the crystals. The atomic structures will be determined using X-ray crystallography
[190, 224, 225]. The structures determined will aid in the development of novel carbohydrate based
vaccines to combat diseases such as cancer.

4.5

TABLES AND FIGURES

Fig. 4.3 SDS-PAGE (Non-reducing and silver stained) of 16A from Dr. Zhou to assess purity.
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Fig. 4.4 Affinity chromatography on Protein A (GE) of 16A testing binding conditions, C
stands for crude, FT stands for flow through, and E stands for elution. The lanes are labeled
as in the figure, with the molecular weight marker to the left of the samples.

Fig. 4.5 Affinity chromatography on Protein G (GE) of 16A testing binding conditions,
FT stands for flow through. The lanes are labeled as in the figure, with the molecular
weight marker to the left of the samples.
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Fig. 4.6 Affinity chromatography on Protein G (GE) of 16A with optimal binding
conditions, FT stands for flow through. E stands for elution. The lanes are labeled as in the
figure, with the molecular weight marker to the left of the samples.

Fig. 4.7 SDS-PAGE of 16A fragmentation with IgG1 mouse preparation
kit at an enzyme to substrate ratio of 1:200. Lane one is the molecular
weight marker. The antibody was then incubated with kit enzyme and
samples were collected at the indicated hours after enzyme incubation.
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Fig. 4.8 SDS-PAGE of 16A fragmentation with immobilized ficin at an enzyme
to substrate ratio of 1:33. The first lane and fourth lane are uncut antibody before
digestion (non-reducing) and (reducing). The antibody was then incubated with
immobilized ficin and samples were collected at 12 hours after enzyme
incubation. The molecular weight marker is in the third lane.

Fig. 4.9 SDS-PAGE of 16A fragmentation with immobilized papain at an
enzyme to substrate ratio of 1:500. The first lane is equilibrated antibody
before digestion (reducing). The antibody was then incubated with
immobilized papain and samples were collected at the hours labeled above
the lanes. The molecular weight marker is to the right of the samples.
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Fig. 4.10 SDS-PAGE of 16A fragmentation with immobilized ficin at an enzyme to
substrate ratio of 1:7. Lane one is the molecular weight marker Lane two is uncut
antibody. The antibody was then incubated with immobilized ficin and samples were
collected at the indicated hours after enzyme incubation.

Fig. 4.11 SDS-PAGE of 16A fragmentation with crystal papain at an enzyme to
substrate ratio of 1:200. Lane one is the molecular weight marker Lane two is
uncut antibody. The antibody was then incubated with papain and samples were
collected at the indicated hours after enzyme incubation.
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Fig. 4.12 SDS-PAGE of 16A fragmentation with crystal papain at an
enzyme to substrate ratio of 1:80. Lane one is the molecular weight marker
Lane two is uncut antibody. The antibody was then incubated with papain
and samples were collected at the indicated hours after enzyme incubation.

Fig. 4.13 SDS-PAGE of 16A fragmentation with IgG1 mouse preparation
kit at an enzyme to substrate ratio of 1:50. Lane one is the molecular
weight marker. The antibody was then incubated with kit enzyme and
samples were collected at the indicated hours after enzyme incubation.
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Fig. 4.14 SDS-PAGE of 16A fragmentation with immobilized papain at an enzyme to
substrate ratio of 1:160. The first lane is uncut antibody before digestion (nonreducing). The antibody was then incubated with immobilized papain and samples
were collected at the hours labeled above the lanes. The molecular weight marker is to
the right of the samples.
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